BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Sherman M;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199] [Cited by in Crossref: 5422] [Cited by in F6Publishing: 4948] [Article Influence: 542.2] [Reference Citation Analysis]
Number Citing Articles
1 Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012;13:1059-1067. [PMID: 22519770 DOI: 10.1517/14656566.2012.679930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
2 Koom WS, Park SY, Kim W, Kim M, Kim JS, Kim H, Choi IK, Yun CO, Seong J. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res 2012;53:202-10. [PMID: 22510592 DOI: 10.1269/jrr.11110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
3 Shim JH, Chung Y, Kim JA, Lee D, Kim KM, Lim Y, Lee HC, Lee YS, Yu E, Lee YJ. Clinical Implications of Arrest-Defective Protein 1 Expression in Hepatocellular Carcinoma: A Novel Predictor of Microvascular Invasion. Dig Dis 2012;30:603-8. [DOI: 10.1159/000343090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
4 Shimagaki T, Yoshizumi T, Harimoto N, Yoshio S, Naito Y, Yamamoto Y, Ochiya T, Yoshida Y, Kanto T, Maehara Y. MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. Hepatol Res. 2018;48:313-321. [PMID: 28984009 DOI: 10.1111/hepr.12990] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
5 Brito AF, Ribeiro M, Abrantes AM, Mamede AC, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF. New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Nutr Cancer 2016;68:250-66. [PMID: 26943884 DOI: 10.1080/01635581.2016.1145245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
6 Lei J, Zhang D, Yao C, Ding S, Lu Z. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis. Cancer Control. 2020;27:1073274820977114. [PMID: 33269615 DOI: 10.1177/1073274820977114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ramos Rubio E, Ortiz de Urbina J, Santoyo Santoyo J, Varo Pérez E. Grado de homogeneidad de los grupos españoles de trasplante hepático en el tratamiento del hepatocarcinoma. Medicina Clínica 2013;141:406-10. [DOI: 10.1016/j.medcli.2013.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Nakayama H, Takayama T. Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol. 2015;7:2292-2302. [PMID: 26380653 DOI: 10.4254/wjh.v7.i20.2292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014;20:11595-617. [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
10 Lencioni R, Crocetti L. Image-guided ablation for hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:181-194. [PMID: 22941021 DOI: 10.1007/978-3-642-16037-0_12] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R. Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. Med Oncol 2016;33:114. [PMID: 27601241 DOI: 10.1007/s12032-016-0827-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Ganne-carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau J, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron J, Tran A, Perlemuter G, Amiot X, Zarski J, Beaugrand M, Chevret S. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. Journal of Hepatology 2018;69:1274-83. [DOI: 10.1016/j.jhep.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
13 Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, Brunello F, Pinna AD, Giorgio A, Giulini SM, De Sio I, Torzilli G, Fornari F, Capussotti L, Guglielmi A, Piscaglia F, Aldrighetti L, Caturelli E, Calise F, Nuzzo G, Rapaccini GL, Giuliante F. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3cm. Results of a multicenter Italian survey. Journal of Hepatology 2013;59:89-97. [DOI: 10.1016/j.jhep.2013.03.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 20.0] [Reference Citation Analysis]
14 Papadatos D, Fowler KJ, Kielar AZ, Cui J, Sirlin CB. Cirrhosis and LI-RADS. Abdom Radiol (NY) 2018;43:26-40. [PMID: 29218367 DOI: 10.1007/s00261-017-1425-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
15 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: A propensity score analysis. Medicine (Baltimore). 2014;93:e264. [PMID: 25526453 DOI: 10.1097/md.0000000000000264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
17 Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Roenn NMV, Berkes JL, Cotler SJ. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Annals of Hepatology 2013;12:766-73. [DOI: 10.1016/s1665-2681(19)31318-3] [Cited by in Crossref: 21] [Article Influence: 2.6] [Reference Citation Analysis]
18 Felli E, Cillo U, Pinna AD, De Carlis L, Ercolani G, Santoro R, Gringeri E, Di Sandro S, Di Laudo M, Di Giunta M, Lauterio A, Colasanti M, Lepiane P, Vennarecci G, Ettorre GM. Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience. Updates Surg 2015;67:215-22. [DOI: 10.1007/s13304-015-0323-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
19 Chen GW, Song B, Li ZL, Yuan Y. Ectopic blood supply of hepatocellular carcinoma as depicted by angiography with computed tomography: associations with morphological features and therapeutic history. PLoS One 2013;8:e71942. [PMID: 23967266 DOI: 10.1371/journal.pone.0071942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
20 Chen S, Peng Z, Xiao H, Lin M, Chen Z, Jiang C, Hu W, Xie X, Liu L, Peng B, Kuang M. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int J Hyperthermia 2018;34:1029-37. [PMID: 28974113 DOI: 10.1080/02656736.2017.1387941] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 de la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, Testillano M, Lorente S, Arenas JI, Gil C, Iñarrairaegui M, Sangro B. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int 2016;36:1206-12. [PMID: 26910784 DOI: 10.1111/liv.13098] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
22 Matsui Y, Figi A, Horikawa M, Jahangiri Noudeh Y, Tomozawa Y, Hashimoto K, Kaufman J, Farsad K. Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. Diagnostic and Interventional Imaging 2017;98:827-35. [DOI: 10.1016/j.diii.2017.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271-8282. [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
24 Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology. 2012;265:104-114. [PMID: 22891358 DOI: 10.1148/radiol.12112649] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
25 Casadei Gardini A, Scarpi E, Foschi FG, Marisi G, Maltoni M, Frassineti GL. Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. Clin Res Hepatol Gastroenterol 2019;43:e76-8. [PMID: 30528062 DOI: 10.1016/j.clinre.2018.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Hong SB, Lee NK, Kim S, Seo HI, Kim HS, Kim DU, Kim TU, Ryu HS. Modified CAIPIRINHA-VIBE without view-sharing on gadoxetic acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE. Eur Radiol 2019;29:3574-83. [PMID: 30993435 DOI: 10.1007/s00330-019-06095-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Wang S, Cui S, Zhao W, Qian Z, Liu H, Chen Y, Lv F, Ding HG. Screening and bioinformatics analysis of circular RNA expression profiles in hepatitis B-related hepatocellular carcinoma. Cancer Biomark. 2018;22:631-640. [PMID: 29914004 DOI: 10.3233/cbm-170910] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
28 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M. Is tumor biopsy necessary? Liver Transpl 2011;17 Suppl 2:S14-25. [PMID: 21744470 DOI: 10.1002/lt.22374] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
30 Liu J, Zhang H, Xia Y, Yang T, Gao Y, Li J, Wu Y, Shen F. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2019;21:1-13. [PMID: 30082213 DOI: 10.1016/j.hpb.2018.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Qi X, Jia J, Fan D, Han G. Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage? J Clin Oncol. 2014;32:968. [PMID: 24516020 DOI: 10.1200/JCO.2013.53.8199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
32 Chen VL, Le AK, Podlaha O, Estevez J, Li B, Vutien P, Chang ET, Rosenberg-Hasson Y, Pflanz S, Jiang Z, Ge D, Gaggar A, Nguyen MH. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers. Sci Rep. 2017;7:11169. [PMID: 28894136 DOI: 10.1038/s41598-017-10498-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Olson JC. Acute-on-chronic and Decompensated Chronic Liver Failure: Definitions, Epidemiology, and Prognostication. Crit Care Clin 2016;32:301-9. [PMID: 27339672 DOI: 10.1016/j.ccc.2016.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Li P, Fan H, He Q. Investigation of the clinical significance and prognostic value of microRNA-145 in human hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13715. [PMID: 30572504 DOI: 10.1097/MD.0000000000013715] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
35 Sun Y, Zhai W, Liu X, Song X, Gao X, Xu K, Tang B. Homotypic cell membrane-cloaked biomimetic nanocarrier for the accurate photothermal-chemotherapy treatment of recurrent hepatocellular carcinoma. J Nanobiotechnology 2020;18:60. [PMID: 32299505 DOI: 10.1186/s12951-020-00617-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W, Ren W. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients. Int J Cancer. 2016;139:928-937. [PMID: 27038145 DOI: 10.1002/ijc.30124] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
37 Gyedu A, Shrauner WR, Kingham TP. No patients to resect or transplant: an analysis of patients with hepatocellular carcinoma admitted to a major African referral hospital. World J Surg 2015;39:231-6. [PMID: 25167899 DOI: 10.1007/s00268-014-2762-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
38 Lewin M, Gelu-simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, Meyer L, Fontaine H, Salmon-céron D, Samuel D, Seror O, Trinchet J, Duclos-vallée J. Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Radiology 2015;277:443-53. [DOI: 10.1148/radiol.2015141500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
39 Hou G, Chen L, Liu G, Li L, Yang Y, Yan HX, Zhang HL, Tang J, Yang YC, Lin X, Chen X, Luo GJ, Zhu Y, Tang S, Zhang J, Liu H, Gu Q, Zhao LH, Li Y, Liu L, Zhou W, Wang H. Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice. Hepatology 2017;65:1628-44. [PMID: 28027570 DOI: 10.1002/hep.29006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
40 Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016;111:70-77. [PMID: 26729544 DOI: 10.1038/ajg.2015.389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
41 Tan T, Xiao Y, Zhou S, Ma C, Zhang Z. Y-configuration stent combined with iodine-125 seeds strand for the treatment of hepatocellular carcinoma with tumor thrombosis in portal vein branches: A case report. Medicine (Baltimore). 2017;96:e8660. [PMID: 29145293 DOI: 10.1097/md.0000000000008660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Thrift AP, Chiao EY. Are Non-HIV Malignancies Increased in the HIV-Infected Population? Curr Infect Dis Rep 2018;20. [DOI: 10.1007/s11908-018-0626-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
43 Yokoo T, Singal AG, Diaz de Leon A, Ananthakrishnan L, Fetzer DT, Pedrosa I, Khatri G. Prevalence and clinical significance of discordant LI-RADS® observations on multiphase contrast-enhanced MRI in patients with cirrhosis. Abdom Radiol 2020;45:177-87. [DOI: 10.1007/s00261-019-02133-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
44 Su L, Zhou T, Zhang Z, Zhang X, Zhi X, Li C, Wang Q, Jia C, Shi W, Yue Y, Gao Y, Cheng B. Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study. BMC Cancer 2016;16:424. [PMID: 27387757 DOI: 10.1186/s12885-016-2420-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
45 Tan J, Lai Z, Liu L, Long W, Chen T, Zha J, Wang L, Chen M, Ji H, Lai Y. ONTD induces apoptosis of human hepatoma Bel-7402 cells via a MAPK-dependent mitochondrial pathway and the depletion of intracellular glutathione. The International Journal of Biochemistry & Cell Biology 2013;45:2632-42. [DOI: 10.1016/j.biocel.2013.08.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell Signal. 2014;26:1030-1039. [PMID: 24486412 DOI: 10.1016/j.cellsig.2014.01.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
47 Zhou X, Wang L, Wang G, Cheng X, Hu S, Ke W, Li M, Zhang Y, Song Z, Zheng Q. A new plasma biomarker enhance the clinical prediction of postoperative acute kidney injury in patients with hepatocellular carcinoma. Clin Chim Acta 2017;475:128-36. [PMID: 29031454 DOI: 10.1016/j.cca.2017.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
48 An J, Chang S, Kim HI, Song GW, Shim JH. The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease. Cancer Med 2019;8:6624-33. [PMID: 31532075 DOI: 10.1002/cam4.2543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
50 Gounder PP, Bulkow LR, Snowball M, Negus S, Spradling PR, McMahon BJ. Hepatocellular Carcinoma Risk in Alaska Native Children and Young Adults with Hepatitis B Virus: Retrospective Cohort Analysis. J Pediatr 2016;178:206-13. [PMID: 27590612 DOI: 10.1016/j.jpeds.2016.08.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
51 Si ZM, Wang GZ, Qian S, Qu XD, Yan ZP, Liu R, Wang JH. Combination Therapies in the Management of Large (≥ 5 cm) Hepatocellular Carcinoma: Microwave Ablation Immediately Followed by Transarterial Chemoembolization. J Vasc Interv Radiol 2016;27:1577-83. [PMID: 27103146 DOI: 10.1016/j.jvir.2016.02.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
52 Wang WT, Yang L, Yang ZX, Hu XX, Ding Y, Yan X, Fu CX, Grimm R, Zeng MS, Rao SX. Assessment of Microvascular Invasion of Hepatocellular Carcinoma with Diffusion Kurtosis Imaging. Radiology 2018;286:571-80. [PMID: 28937853 DOI: 10.1148/radiol.2017170515] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 13.5] [Reference Citation Analysis]
53 Yu SJ, Kwon JH, Kim W, Yoon J, Lee JM, Lee JY, Cho EJ, Lee J, Kim HY, Jung YJ, Kim YJ. Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. Journal of Clinical Gastroenterology 2018;52:e18-26. [DOI: 10.1097/mcg.0000000000000841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
55 Lertpipopmetha K, Tubtawee T, Piratvisuth T, Chamroonkul N. Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2016;17:4805-11. [PMID: 28030903 DOI: 10.22034/APJCP.2016.17.11.4805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun 2017;1:18-22. [PMID: 29404430 DOI: 10.1002/hep4.1014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020;3:e2021173. [PMID: 33206188 DOI: 10.1001/jamanetworkopen.2020.21173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Beard RE, Hanto DW, Gautam S, Miksad RA. A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery. 2013;154:545-555. [PMID: 23777589 DOI: 10.1016/j.surg.2013.02.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
59 Gong ZJ, Guo W, Sun YF, Zhang X, Qiu SJ, Zhou J, Fan J, Yang XR. Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. Onco Targets Ther 2016;9:6281-90. [PMID: 27789960 DOI: 10.2147/OTT.S109023] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology 2018;67:612-22. [PMID: 28898447 DOI: 10.1002/hep.29515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
61 Zhao M, Xiang P, Jiang H. TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis. Int J Surg 2018;53:151-8. [PMID: 29602011 DOI: 10.1016/j.ijsu.2018.03.049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
62 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
63 He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PMID: 31070690 DOI: 10.1001/jamaoncol.2019.0250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 62.0] [Reference Citation Analysis]
64 Kim HC, Seo N, Chung YE, Park MS, Choi JY, Kim MJ. Characterization of focal liver lesions using the stretched exponential model: comparison with monoexponential and biexponential diffusion-weighted magnetic resonance imaging. Eur Radiol 2019;29:5111-20. [PMID: 30796578 DOI: 10.1007/s00330-019-06048-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
65 Qiao Y, Chen J, Li X, Wei H, Xiao F, Chang L, Zhang R, Hao X, Wei H. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem. 2014;47:216-222. [PMID: 25168922 DOI: 10.1016/j.clinbiochem.2014.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
66 Sun FK, Fan YC, Zhao J, Zhang F, Gao S, Zhao ZH, Sun Q, Wang K. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig Dis Sci. 2013;58:1010-1015. [PMID: 23108564 DOI: 10.1007/s10620-012-2462-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
67 Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Hepatology. 2017;65:122-133. [PMID: 27770556 DOI: 10.1002/hep.28881] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
68 Zhou Z, Wu S, Wang CY, Ma HY, Lin CC, Tsui PH. Monitoring radiofrequency ablation using real-time ultrasound Nakagami imaging combined with frequency and temporal compounding techniques. PLoS One 2015;10:e0118030. [PMID: 25658424 DOI: 10.1371/journal.pone.0118030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
69 Tomozawa Y, Nitta N, Ohta S, Watanabe S, Sonoda A, Nitta-seko A, Tsuchiya K, Murata K. Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model. Cardiovasc Intervent Radiol 2017;40:1763-8. [DOI: 10.1007/s00270-017-1719-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Kim SS, Hwang JA, Shin HC, Choi S, Kang TW, Jou SS, Lee WH, Park S, Heo NH. LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy? Eur Radiol 2019;29:186-94. [DOI: 10.1007/s00330-018-5657-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
71 Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 115] [Article Influence: 30.0] [Reference Citation Analysis]
72 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Song KD, Lee MW, Rhim H, Kang TW, Cha DI, Sinn DH, Lim HK. Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. Radiology. 2018;288:878-886. [PMID: 29916771 DOI: 10.1148/radiol.2018172743] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
74 Donadon M, Costa G, Cimino M, Procopio F, Fabbro DD, Palmisano A, Torzilli G. Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score. World J Surg. 2015;39:237-243. [PMID: 25217112 DOI: 10.1007/s00268-014-2786-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
75 Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927-33.e2. [PMID: 24582947 DOI: 10.1016/j.cgh.2014.02.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
76 Parikh ND, Scaglione S, Li Y, Powell C, Yerokun OA, Devlin P, Mumtaz S, Mittal S, Singal AG. A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort. Clin Gastroenterol Hepatol. 2018;16:781-782. [PMID: 28987503 DOI: 10.1016/j.cgh.2017.10.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
77 He W, Zheng Y, Zou R, Shen J, Yang J, Qiu J, Tao Q, Liu W, Yang Z, Zhang Y, Li B, Yuan Y. Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Commun (Lond) 2018;38:26. [PMID: 29784036 DOI: 10.1186/s40880-018-0296-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
78 Kim H, Lee SJ, Yoon M. Alpha-fetoprotein is correlated with intrahepatic recurrence of hepatocellular carcinoma after a hepatectomy. Ann Surg Treat Res 2020;98:168-76. [PMID: 32274364 DOI: 10.4174/astr.2020.98.4.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Xu X, Liu X, Liang M, Luo B. Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology 2018;287:461-72. [DOI: 10.1148/radiol.2017162756] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 22.0] [Reference Citation Analysis]
80 Vukotic R, Di Donato R, Conti F, Scuteri A, Serra C, Andreone P. Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort. J Viral Hepat. 2017;24:13-16. [PMID: 27905669 DOI: 10.1111/jvh.12651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
81 Orman ES, Hayashi PH. Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2013;105:667. [PMID: 23591462 DOI: 10.1093/jnci/djt061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Lee M, Baek SE, Moon J, Roh YH, Lim JS, Park MS, Kim MJ, Kim H. Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis. Oncotarget 2016;7:38513-22. [PMID: 27229529 DOI: 10.18632/oncotarget.9567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
83 John JA, de Mattos AA, da Silva Miozzo SA, Comerlato PH, Porto M, Contiero P, da Silva RR. Survival and risk factors related to death in outpatients with cirrhosis treated in a clinic in Southern Brazil. Eur J Gastroenterol Hepatol. 2015;27:1372-1377. [PMID: 26426832 DOI: 10.1097/meg.0000000000000480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One 2018;13:e0204412. [PMID: 30260995 DOI: 10.1371/journal.pone.0204412] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
85 Meng XY, Zhang XP, Sun Z, Wang HQ, Yu WF. Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. BMC Anesthesiol 2020;20:233. [PMID: 32928121 DOI: 10.1186/s12871-020-01111-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Que J, Wu HC, Lin CH, Huang CI, Li LC, Ho CH. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine (Baltimore) 2020;99:e19660. [PMID: 32221093 DOI: 10.1097/MD.0000000000019660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
87 Jia Y, Zeng Z, Li Y, Li Z, Jin L, Zhang Z, Wang L, Wang FS. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PLoS One. 2015;10:e0117458. [PMID: 25689070 DOI: 10.1371/journal.pone.0117458] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
88 Shi S, Chen Q, Ye L, Yin D, Li X, Dai Z, He J. Prognostic value of systemic inflammation score in patients with hepatocellular carcinoma after hepatectomy. Oncotarget 2017;8:79366-75. [PMID: 29108315 DOI: 10.18632/oncotarget.18121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
89 Mizandari M, Azrumelashvili T, Paksashvili N, Kikodze N, Pantsulaia Ia, Janikashvili N, Chikovani T. Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation. Case Reports Hepatol 2016;2016:6843121. [PMID: 27579192 DOI: 10.1155/2016/6843121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
90 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
91 van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen H, Jansen PL, Ijzermans JN, Verheij J, van Nieuwkerk CM, Siersema PD, de Man RA. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. European Journal of Gastroenterology & Hepatology 2016;28:352-9. [DOI: 10.1097/meg.0000000000000527] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
92 Muenzel D, Lo GC, Yu HS, Parakh A, Patino M, Kambadakone A, Rummeny EJ, Sahani DV. Material density iodine images in dual-energy CT: Detection and characterization of hypervascular liver lesions compared to magnetic resonance imaging. Eur J Radiol 2017;95:300-6. [PMID: 28987684 DOI: 10.1016/j.ejrad.2017.08.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
93 Hernández-Guerra M, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. United European Gastroenterol J 2015;3:284-93. [PMID: 26279838 DOI: 10.1177/2050640615575971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
94 Chua DW, Koh YX, Syn NL, Chuan TY, Yao TJ, Lee SY, Goh BKP, Cheow PC, Chung AY, Chan CY. Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis. Ann Surg Oncol 2021. [PMID: 33969464 DOI: 10.1245/s10434-021-09948-2] [Reference Citation Analysis]
95 Wu J, Sun C, Li E, Wang J, He X, Yuan R, Yi C, Liao W, Wu L. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality. BMC Cancer 2019;19:334. [PMID: 30961556 DOI: 10.1186/s12885-019-5543-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
96 Zhou S, Shen J, Lin S, Liu X, Xu M, Shi L, Wang X, Cai X. Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis. Tumor Biol 2016;37:13607-16. [DOI: 10.1007/s13277-016-5213-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
97 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 12.2] [Reference Citation Analysis]
98 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 192] [Article Influence: 40.3] [Reference Citation Analysis]
99 Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. Am J Gastroenterol 2016;111:1573-80. [PMID: 27527741 DOI: 10.1038/ajg.2016.330] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
100 Cillo U, Vitale A, Dupuis D, Corso S, Neri D, D'Amico F, Gringeri E, Farinati F, Vincenzi V, Zanus G. Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study. PLoS One 2013;8:e57249. [PMID: 23437351 DOI: 10.1371/journal.pone.0057249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
101 Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol. 2012;10:163. [PMID: 22897815 DOI: 10.1186/1477-7819-10-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
102 Branco F, Alencar RS, Volt F, Sartori G, Dode A, Kikuchi L, Tani CM, Chagas AL, Pfiffer T, Hoff P, Carrilho FJ, Alves de Mattos A. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. Annals of Hepatology 2017;16:263-8. [DOI: 10.5604/16652681.1231587] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
103 Civan JM. Liver Transplantation for HCC: The Milan Criteria. In: Doria C, editor. Contemporary Liver Transplantation. Cham: Springer International Publishing; 2016. pp. 1-19. [DOI: 10.1007/978-3-319-05543-5_11-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
104 Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
105 Bissoondial TL, Han Y, Mullan S, Pabla AK, Spahn K, Shi S, Zheng L, Zhou P, Jiang K, Prakash N, Bhutkar S, Ali Q, Li J, Hu Z, Pellicano AJ, Goldberg ID, Narayan P. Liver Biopsy Hydroxyproline Content Is a Diagnostic for Hepatocellular Carcinoma in Murine Models of Nonalcoholic Steatohepatitis. Diagnostics (Basel) 2020;10:E784. [PMID: 33020436 DOI: 10.3390/diagnostics10100784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
106 Wang D, Yang C, Wang Z, Yang Y, Li D, Ding X, Xu W, Zheng Q. Norcantharidin combined with Coix seed oil synergistically induces apoptosis and inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation. Sci Rep 2017;7:9373. [PMID: 28839202 DOI: 10.1038/s41598-017-09668-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
107 Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, Wada H, Kawamoto K, Eguchi H, Konno M, Ishii H, Umeshita K, Doki Y, Mori M. Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol 2014;21 Suppl 4:S591-600. [PMID: 24740829 DOI: 10.1245/s10434-014-3705-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
108 Goh MJ, Oh JH, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer 2021;10:52-62. [PMID: 33708639 DOI: 10.1159/000512239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
109 Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21:1189-1196. [PMID: 25632192 DOI: 10.3748/wjg.v21.i4.1189] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
110 Maruyama H, Kondo T, Sekimoto T, Takahashi M, Fujiwara K, Imazeki F, Yokosuka O. Retrograde detection of the intrahepatic portal vein in primary biliary cirrhosis: is sinusoidal blockage the underlying pathophysiology? Eur J Gastroenterol Hepatol. 2015;27:321-327. [PMID: 25563140 DOI: 10.1097/meg.0000000000000268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
111 Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66. [PMID: 27932229 DOI: 10.1016/s0140-6736(16)32453-9] [Cited by in Crossref: 1429] [Cited by in F6Publishing: 800] [Article Influence: 285.8] [Reference Citation Analysis]
112 Agni RM. Diagnostic histopathology of hepatocellular carcinoma: A case-based review. Semin Diagn Pathol. 2017;34:126-137. [PMID: 28143798 DOI: 10.1053/j.semdp.2016.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
113 Korean Society of Abdominal Radiology. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-43. [PMID: 28458595 DOI: 10.3348/kjr.2017.18.3.427] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
114 Lin YY, Chen CM, Huang YH, Lin CY, Chu SY, Hsu MY, Pan KT, Tseng JH. Liver metastasis from hepatoid adenocarcinoma of the stomach mimicking hepatocellular carcinoma: Dynamic computed tomography findings. World J Gastroenterol 2015;21:13524-31. [PMID: 26730164 DOI: 10.3748/wjg.v21.i48.13524] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
115 Furlan A, Close O, Borhani A, Wu Y, Heller M. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients. Clinical Radiology 2017;72:93.e1-6. [DOI: 10.1016/j.crad.2016.08.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
116 Kim SE, Lee HC, Shim JH, Park HJ, Kim KM, Kim PN, Shin YM, Yu ES, Chung YH, Suh DJ. Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses > 2 cm in a hepatitis B virus-endemic area. Liver Int. 2011;31:1468-1476. [PMID: 21745284 DOI: 10.1111/j.1478-3231.2011.02529.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
117 Midorikawa Y, Takayama T, Nara S, Hashimoto T, Omichi K, Ebisawa K, Higaki T, Tsuji S, Sakamoto H, Shimada K, Makuuchi M. No Need of Immediate Treatment for Hypovascular Tumors Associated with Hepatocellular Carcinoma. World J Surg 2016;40:2460-5. [PMID: 27142625 DOI: 10.1007/s00268-016-3548-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 An C, Kim MJ. Imaging features related with prognosis of hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:509-16. [PMID: 30171295 DOI: 10.1007/s00261-018-1758-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
119 Huang XC, Pang FX, Ou SS, Wei XJ, Xu YJ, Lai YH. Risk Score Based on Two microRNAs as a Prognostic Marker of Hepatocellular Carcinoma and the Corresponding Competitive Endogenous RNA Network. Int J Gen Med 2021;14:3377-85. [PMID: 34285562 DOI: 10.2147/IJGM.S318516] [Reference Citation Analysis]
120 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
121 Cheung KS, Seto WK, Wong DK, Lai CL, Yuen MF. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat. 2017;24:654-661. [PMID: 28185363 DOI: 10.1111/jvh.12688] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
122 Song KD, Jeong WK. Benign nodules mimicking hepatocellular carcinoma on gadoxetic acid-enhanced liver MRI. Clin Mol Hepatol. 2015;21:187-191. [PMID: 26157758 DOI: 10.3350/cmh.2015.21.2.187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
123 Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Dig Dis. 2011;29:273-277. [PMID: 21829017 DOI: 10.1159/000327558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
124 Kim BK, Shim JH, Kim SU, Park JY, Kim DY, Ahn SH, Kim KM, Lim YS, Han KH, Lee HC. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016;36:92-99. [PMID: 25950442 DOI: 10.1111/liv.12865] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
125 Chen Z, Xu L, Su T, Ke Z, Peng Z, Zhang N, Peng S, Zhang Q, Liu G, Wei G, Guo Y, He M, Kuang M. Autocrine STIP1 signaling promotes tumor growth and is associated with disease outcome in hepatocellular carcinoma. Biochem Biophys Res Commun 2017;493:365-72. [PMID: 28887036 DOI: 10.1016/j.bbrc.2017.09.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
126 Lin M, Chang K, Chou Y, Tseng P, Yen Y, Wang C, Tsai M, Cheng Y, Eng H, Wu C, Hu T. The validation of the 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area: Image diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2015;30:345-51. [DOI: 10.1111/jgh.12699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
127 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
128 Lin CH, Ho CM, Wu CH, Liang PC, Wu YM, Hu RH, Lee PH, Ho MC. Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis. Surg Endosc 2020;34:5566-73. [PMID: 31993821 DOI: 10.1007/s00464-019-07357-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis. 2012;16:839-850. [PMID: 23101985 DOI: 10.1016/j.cld.2012.08.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
130 Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol 2020;11:e00140. [PMID: 32352711 DOI: 10.14309/ctg.0000000000000140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
131 Capurro M, Martin T, Shi W, Filmus J. Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling. Journal of Cell Science. [DOI: 10.1242/jcs.140871] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 13.0] [Reference Citation Analysis]
132 Venkatesh SK, Hennedige T, Johnson GB, Hough DM, Fletcher JG. Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdom Radiol (NY) 2017;42:1374-92. [PMID: 27999887 DOI: 10.1007/s00261-016-1002-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
133 Park VY, Choi JY, Chung YE, Kim H, Park MS, Lim JS, Kim KW, Kim MJ. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014;34:1593-602. [PMID: 24673802 DOI: 10.1111/liv.12550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
134 Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. European Journal of Gastroenterology & Hepatology 2012;24:195-202. [DOI: 10.1097/meg.0b013e32834e153c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
135 Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore) 2020;99:e18948. [PMID: 32028404 DOI: 10.1097/MD.0000000000018948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
136 Wang J, Shan Q, Liu Y, Yang H, Kuang S, He B, Zhang Y, Chen J, Zhang T, Glaser KJ, Zhu C, Chen J, Yin M, Venkatesh SK, Ehman RL. 3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence. J Magn Reson Imaging 2019;49:719-30. [PMID: 30260529 DOI: 10.1002/jmri.26250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
137 Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131. [PMID: 30453925 DOI: 10.1186/s12885-018-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
138 Hyun D, Shin SW, Cho SK, Park KB, Park HS, Choo SW, Do YS, Choo I, Shin J, Lim S. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol 2015;56:1437-45. [DOI: 10.1177/0284185114560937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
139 Liu D, Chan AC, Fong DY, Lo CM, Khong PL. Evidence-Based Surveillance Imaging Schedule After Liver Transplantation for Hepatocellular Carcinoma Recurrence. Transplantation. 2017;101:107-111. [PMID: 28009758 DOI: 10.1097/tp.0000000000001513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
140 Ricke J, Seidensticker M, Mohnike K. Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. Liver Cancer 2012;1:51-8. [PMID: 24159571 DOI: 10.1159/000339020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
141 Ajit Y, Sudarsan H, Saumya G, Abhishek A, Navneet R, Piyush R, Anil A, Arun G. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J. 2014;29:430-436. [PMID: 25584161 DOI: 10.5001/omj.2014.114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
142 D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532-543. [PMID: 22271347 DOI: 10.1002/hep.25606] [Cited by in Crossref: 261] [Cited by in F6Publishing: 232] [Article Influence: 29.0] [Reference Citation Analysis]
143 Lin S, Lin Y, Fang Y, Mo Z, Hong X, Ji C, Jian Z. Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients. Medicine (Baltimore) 2021;100:e24153. [PMID: 33546030 DOI: 10.1097/MD.0000000000024153] [Reference Citation Analysis]
144 Elwan N, Salem ML, Kobtan A, El-Kalla F, Mansour L, Yousef M, Al-Sabbagh A, Zidan AA, Abd-Elsalam S. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol Invest. 2018;47:169-180. [PMID: 29182438 DOI: 10.1080/08820139.2017.1407787] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
145 Choi SH, Byun JH, Lim YS, Yu E, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 2016;64:1099-107. [PMID: 26820629 DOI: 10.1016/j.jhep.2016.01.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]
146 Zhao Y, Zhu X, Wang H, Dong D, Gao S, Zhu X, Wang W. Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion. Front Oncol. 2019;9:1065. [PMID: 31681599 DOI: 10.3389/fonc.2019.01065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
147 Zhang J, Jiang TY, Jiang BG, Yang C, Tan YX, Yang N, Pan YF, Ding ZW, Yang GZ, Wu MC, Dong LW, Wang HY. RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. Oncotarget 2015;6:3432-42. [PMID: 25605019 DOI: 10.18632/oncotarget.3092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
148 Song KD, Lee MW, Rhim H, Cha DI, Chong Y, Lim HK. Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol. 2013;201:1141-1147. [PMID: 24147489 DOI: 10.2214/ajr.13.10532] [Cited by in Crossref: 58] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
149 Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr. 2014;3:410-414. [PMID: 25568864 DOI: 10.3978/j.issn.2304-3881.2014.07.06] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
150 Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014;44:1179-85. [PMID: 24171787 DOI: 10.1111/hepr.12266] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
151 Li HH, Qi LN, Ma L, Chen ZS, Xiang BD, Li LQ. Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion. Onco Targets Ther 2018;11:4747-54. [PMID: 30127623 DOI: 10.2147/OTT.S165244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
152 Chang W, Lee JM, Lee DH, Yoon JH, Kim YJ, Yoon JH, Han JK. Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial. PLoS One 2018;13:e0192173. [PMID: 29420589 DOI: 10.1371/journal.pone.0192173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
153 Elsanousi OM, Mohamed MA, Salim FH, Adam EA. Selective devascularization treatment for large hepatocellular carcinoma: Stage 2A IDEAL prospective case series.Int J Surg. 2019;68:134-141. [PMID: 31265917 DOI: 10.1016/j.ijsu.2019.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Knieling F, Waldner MJ, Goertz RS, Strobel D. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Rep. 2012;2012. [PMID: 23257272 DOI: 10.1136/bcr-2012-007576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
155 Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. J Clin Oncol. 2017;35:622-628. [PMID: 28045619 DOI: 10.1200/jco.2016.69.5197] [Cited by in Crossref: 69] [Cited by in F6Publishing: 42] [Article Influence: 17.3] [Reference Citation Analysis]
156 Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F;  ITA. LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: an update.Liver Int. 2021;41:585-597. [PMID: 33219585 DOI: 10.1111/liv.14735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
157 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 225] [Article Influence: 27.2] [Reference Citation Analysis]
158 Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-68. [PMID: 26280007 DOI: 10.1159/000343875] [Cited by in Crossref: 274] [Cited by in F6Publishing: 258] [Article Influence: 45.7] [Reference Citation Analysis]
159 Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg. 2015;39:1150-1160. [PMID: 25634340 DOI: 10.1007/s00268-015-2956-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
160 Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P. Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: A protein-based hepatocellular carcinoma-associated study. Indian J Med Res 2018;147:361-8. [PMID: 29998871 DOI: 10.4103/ijmr.IJMR_1358_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
161 Kim JW, Shin SS, Kim JK, Choi SK, Heo SH, Lim HS, Hur YH, Cho CK, Jeong YY, Kang HK. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol. 2013;14:626-635. [PMID: 23901320 DOI: 10.3348/kjr.2013.14.4.626] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
162 Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015;7:1521-9. [PMID: 26085911 DOI: 10.4254/wjh.v7.i11.1521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
163 Cai H, Zhu XD, Ao JY, Ye BG, Zhang YY, Chai ZT, Wang CH, Shi WK, Cao MQ, Li XL, Sun HC. Colony-stimulating factor-1-induced AIF1 expression in tumor-associated macrophages enhances the progression of hepatocellular carcinoma. Oncoimmunology 2017;6:e1333213. [PMID: 28932635 DOI: 10.1080/2162402X.2017.1333213] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
164 Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco). Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014;16:758-767. [PMID: 24467780 DOI: 10.1111/hpb.12214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
165 Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 Radioembolization for Hepatocellular Carcinoma. Seminars in Nuclear Medicine 2016;46:105-8. [DOI: 10.1053/j.semnuclmed.2015.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
166 Galassi M, Iavarone M, Rossi S, Bota S, Vavassori S, Rosa L, Leoni S, Venerandi L, Marinelli S, Sangiovanni A, Veronese L, Fraquelli M, Granito A, Golfieri R, Colombo M, Bolondi L, Piscaglia F. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int. 2013;33:771-779. [PMID: 23445369 DOI: 10.1111/liv.12124] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
167 Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. PharmGKB summary: sorafenib pathways. Pharmacogenet Genomics 2017;27:240-6. [PMID: 28362716 DOI: 10.1097/FPC.0000000000000279] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
168 Ronot M, Fouque O, Esvan M, Lebigot J, Aubé C, Vilgrain V. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm. J Hepatol 2018;68:715-23. [PMID: 29274407 DOI: 10.1016/j.jhep.2017.12.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 12.8] [Reference Citation Analysis]
169 Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle. 2013;12:1999-2010. [PMID: 23759595 DOI: 10.4161/cc.25099] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
170 Sposito C, Battiston C, Facciorusso A, Mazzola M, Muscarà C, Scotti M, Romito R, Mariani L, Mazzaferro V. Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:871-880. [PMID: 27029597 DOI: 10.1002/bjs.10137] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 16.4] [Reference Citation Analysis]
171 Yuan BH, Yuan WP, Li RH, Xiang BD, Gong WF, Li LQ, Zhong JH. Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol. 2016;37:2435-2441. [PMID: 26383523 DOI: 10.1007/s13277-015-4091-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
172 Han SB, Kim YK, Min JH, Ha SY, Jeong WK, Lee WJ. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Acta Radiol 2018;59:393-401. [PMID: 28760004 DOI: 10.1177/0284185117723040] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Lersritwimanmaen P, Nimanong S. Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. Euroasian J Hepatogastroenterol 2018;8:83-7. [PMID: 29963472 DOI: 10.5005/jp-journals-10018-1268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
174 Malik S, Dekio F, Wen JW. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatr Transplantation 2014;18:E64-8. [DOI: 10.1111/petr.12223] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
175 Guo HL, Chen LD, Li W, Liang JY, Zhang JC, Li X, Xie XY, Lu MD, Kuang M, Wang W. Ultrasomics for Early Evaluation of the Tumor Response to MicroRNA-122 in a Nude Mouse Hepatocellular Carcinoma Model. J Ultrasound Med 2020;39:61-71. [PMID: 31225651 DOI: 10.1002/jum.15071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Jang S, Lee JM, Lee DH, Joo I, Yoon JH, Chang W, Han JK. Value of MR elastography for the preoperative estimation of liver regeneration capacity in patients with hepatocellular carcinoma. J Magn Reson Imaging 2017;45:1627-36. [PMID: 27859840 DOI: 10.1002/jmri.25517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
177 Wang Z, Wu Q, Feng S, Zhao Y, Tao C. Identification of four prognostic LncRNAs for survival prediction of patients with hepatocellular carcinoma. PeerJ. 2017;5:e3575. [PMID: 28729955 DOI: 10.7717/peerj.3575] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
178 Facciorusso A, Del Prete V, Antonino M, Neve V, Amoruso A, Crucinio N, Di Leo A, Barone M. Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatol Res. 2015;45:E62-E72. [PMID: 25472869 DOI: 10.1111/hepr.12458] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
179 Yang W, Wei J, Sun T, Liu F. Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat Oncol. 2013;8:102. [PMID: 23618526 DOI: 10.1186/1748-717x-8-102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
180 Sano K, Ichikawa T, Motosugi U, Ichikawa S, Morisaka H, Enomoto N, Matsuda M, Fujii H. Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis. Eur Radiol. 2017;27:518-525. [PMID: 27255397 DOI: 10.1007/s00330-016-4423-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
181 Wang J, Huang A, Wang YP, Yin Y, Fu PY, Zhang X, Zhou J. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma. Ann Transl Med 2020;8:237. [PMID: 32309384 DOI: 10.21037/atm.2019.12.154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
182 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
183 Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67:1204-1212. [PMID: 28802876 DOI: 10.1016/j.jhep.2017.07.025] [Cited by in Crossref: 253] [Cited by in F6Publishing: 222] [Article Influence: 63.3] [Reference Citation Analysis]
184 Hwang J, Kim YK, Park MJ, Lee MH, Kim SH, Lee WJ, Choi D. Liver MRI at 3.0 tesla: comparison of image quality and lesion detectability between single-source conventional and dual-source parallel radiofrequency transmissions. J Comput Assist Tomogr. 2012;36:546-553. [PMID: 22992605 DOI: 10.1097/rct.0b013e318264e4a7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
185 Baron Toaldo M, Salvatore V, Marinelli S, Palamà C, Milazzo M, Croci L, Venerandi L, Cipone M, Bolondi L, Piscaglia F. Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Mol Imaging Biol. 2014;Epub ahead of print. [PMID: 25082536 DOI: 10.1007/s11307-014-0764-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
186 De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50:1115-1123. [PMID: 30217732 DOI: 10.1016/j.dld.2018.08.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
187 Guarneri A, Franco P, Trino E, Campion D, Faletti R, Mirabella S, Gaia S, Ragona R, Diotallevi M, Saracco G, Salizzoni M, Ricardi U, Carucci P. Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm. Med Oncol 2016;33. [DOI: 10.1007/s12032-016-0823-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
188 Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol 2014;21:758-66. [PMID: 24006095 DOI: 10.1245/s10434-013-3254-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
189 Chung SR, Kim JH, Yoon HK, Ko GY, Gwon DI, Shin JH, Song HY, Ko HK, Yoon SM. Combined Cisplatin-Based Chemoembolization and Radiation Therapy for Hepatocellular Carcinoma Invading the Main Portal Vein. J Vasc Interv Radiol. 2015;26:1130-1138. [PMID: 26119202 DOI: 10.1016/j.jvir.2015.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
190 Tian MM, Fan YC, Zhao J, Gao S, Zhao ZH, Chen LY, Wang K. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B. Clin Res Hepatol Gastroenterol 2017;41:171-80. [PMID: 28189396 DOI: 10.1016/j.clinre.2016.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
191 Aubé C, Bazeries P, Lebigot J, Cartier V, Boursier J. Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. Diagnostic and Interventional Imaging 2017;98:455-68. [DOI: 10.1016/j.diii.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
192 Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, Tublin ME. Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know. RadioGraphics 2015;35:371-86. [DOI: 10.1148/rg.352140114] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
193 Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol 2020;26:393-403. [PMID: 32063688 DOI: 10.3748/wjg.v26.i4.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
194 Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708-718. [PMID: 22187634 DOI: 10.1148/radiol.11110282] [Cited by in Crossref: 186] [Cited by in F6Publishing: 170] [Article Influence: 18.6] [Reference Citation Analysis]
195 Woo JH, Song KD, Kim SH. Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Outcomes of early treatment and watchful waiting. Eur Radiol. 2017;27:4406-4414. [PMID: 28386720 DOI: 10.1007/s00330-017-4818-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
196 Yopp AC, Singal AG. Epithelial to mesenchymal transition expression profiles as predictive biomarkers of recurrence following resection of HCC: implications for current clinical use and future stratification for systemic therapy. Ann Surg Oncol 2014;21:3723-4. [PMID: 25074660 DOI: 10.1245/s10434-014-3790-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
197 Fu L, Wu S, Yao T, Chen Q, Xie Y, Ying S, Chen Z, Xiao B, Hu Y. Decreased expression of hsa_circ_0003570 in hepatocellular carcinoma and its clinical significance. J Clin Lab Anal. 2018;32. [PMID: 28493512 DOI: 10.1002/jcla.22239] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 10.5] [Reference Citation Analysis]
198 Chow PK, Gandhi M, Gebski V. The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma. Future Oncology 2017;13:2213-6. [DOI: 10.2217/fon-2017-0395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
199 Hsiao WD, Peng CY, Chuang PH, Lai HC, Cheng KS, Chou JW, Chen YY, Yu CJ, Feng CL, Su WP, Chen SH, Kao JT. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol 2016;16:50. [PMID: 27117280 DOI: 10.1186/s12876-016-0464-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
200 Shamaa MM. Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins. FEBS Open Bio 2021;11:588-97. [PMID: 33289342 DOI: 10.1002/2211-5463.13052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Kim SK, Kim H, Koh GY, Lim DS, Yu DY, Kim MD, Park MS, Lim JS. Mouse Hepatic Tumor Vascular Imaging by Experimental Selective Angiography. PLoS One 2015;10:e0131687. [PMID: 26131558 DOI: 10.1371/journal.pone.0131687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
202 Choi JW, Park J, Baek SY, Kim D, Kim H, Cho H. Doxorubicin-loaded poly(lactic-co-glycolic acid) microspheres prepared using the solid-in-oil-in-water method for the transarterial chemoembolization of a liver tumor. Colloids and Surfaces B: Biointerfaces 2015;132:305-12. [DOI: 10.1016/j.colsurfb.2015.05.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
203 He ZX, Xiang P, Gong JP, Cheng NS, Zhang W. Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review. Ther Clin Risk Manag 2016;12:295-303. [PMID: 26966370 DOI: 10.2147/TCRM.S96760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
204 Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, El-Tawdi AHF. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res 2016;168:134-45. [PMID: 26551349 DOI: 10.1016/j.trsl.2015.10.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
205 Zhang B, Wei G, Li R, Wang Y, Yu J, Wang R, Xiao H, Wu C, Leng C, Zhang B, Chen X. n-3 fatty acid-based parenteral nutrition improves postoperative recovery for cirrhotic patients with liver cancer: A randomized controlled clinical trial. Clinical Nutrition 2017;36:1239-44. [DOI: 10.1016/j.clnu.2016.08.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
206 Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 2013;57:1826-37. [DOI: 10.1002/hep.26014] [Cited by in Crossref: 290] [Cited by in F6Publishing: 255] [Article Influence: 36.3] [Reference Citation Analysis]
207 Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, Kudo M, Murakami T. Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration. Cancers (Basel) 2021;13:1460. [PMID: 33806751 DOI: 10.3390/cancers13061460] [Reference Citation Analysis]
208 Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-66. [PMID: 28061016 DOI: 10.1111/liv.13357] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
209 Yu X, Ge N, Guo X, Shen S, Liang J, Huang X, Wan S, Xing J, Huang Q, Yang Y. Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus. PLoS One 2014;9:e93416. [PMID: 24718422 DOI: 10.1371/journal.pone.0093416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
210 Dunne RM, Shyn PB, Sung JC, Tatli S, Morrison PR, Catalano PJ, Silverman SG. Percutaneous treatment of hepatocellular carcinoma in patients with cirrhosis: a comparison of the safety of cryoablation and radiofrequency ablation. Eur J Radiol. 2014;83:632-638. [PMID: 24529593 DOI: 10.1016/j.ejrad.2014.01.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
211 Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol 2013;19:321-7. [PMID: 23372352 DOI: 10.3748/wjg.v19.i3.321] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 65] [Article Influence: 12.1] [Reference Citation Analysis]
212 Huh J, Kim SY, Yeh BM, Lee SS, Kim KW, Wu EH, Wang ZJ, Zhao LQ, Chang WC. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver. Korean J Radiol. 2015;16:1207-1215. [PMID: 26576109 DOI: 10.3348/kjr.2015.16.6.1207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
213 Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, Ali HA, Lee M, Cheung R, Roberts L, Schwartz M, Nguyen MH. Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol 2019;114:80-8. [DOI: 10.1038/s41395-018-0261-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
214 Vitale A, Boccagni P, Kertusha X, Zanus G, D'Amico F, Lodo E, Pastorelli D, Ramirez Morales R, Lombardi G, Senzolo M, Burra P, Cillo U. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc. 2012;44:1989-1991. [PMID: 22974889 DOI: 10.1016/j.transproceed.2012.06.046] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
215 Dai Y, Li C, Wen TF, Yan LN. Comparison of liver resection and transplantation for Child-pugh A cirrhotic patient with very early hepatocellular carcinoma and portal hypertension. Pak J Med Sci. 2014;30:996-1000. [PMID: 25225514 DOI: 10.12669/pjms.305.5038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
216 Khalili K, Menezes R, Yazdi LK, Jang HJ, Kim TK, Sharma S, Feld J, Sherman M. Hepatocellular carcinoma in a large Canadian urban centre: stage at treatment and its potential determinants. Can J Gastroenterol Hepatol. 2014;28:150-154. [PMID: 24619637 DOI: 10.1155/2014/561732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
217 Cerny M, Bergeron C, Billiard JS, Murphy-Lavallée J, Olivié D, Bérubé J, Fan B, Castel H, Turcotte S, Perreault P, Chagnon M, Tang A. LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features. Radiology 2018;288:118-28. [PMID: 29634435 DOI: 10.1148/radiol.2018171678] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 19.7] [Reference Citation Analysis]
218 Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology 2012;39:473-85. [DOI: 10.1053/j.seminoncol.2012.05.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
219 Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7:926-941. [PMID: 25954476 DOI: 10.4254/wjh.v7.i7.926] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
220 Zhang W, Luo E, Gan J, Song X, Bao Z, Zhang H, Chen M. Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound. World J Surg Oncol 2017;15:122. [PMID: 28679433 DOI: 10.1186/s12957-017-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
221 Zhang C, Xia R, Zhang B, Wang H. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma. BMC Cancer 2018;18:1110. [PMID: 30424721 DOI: 10.1186/s12885-018-5017-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
222 Li S, Yang Y, Ding X, Yang M, She S, Peng H, Xu X, Ran X, Li S, Hu P, Hu H, Zhang D, Ren H. LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study. Oncotarget 2017;8:4549-62. [PMID: 27999186 DOI: 10.18632/oncotarget.13941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
223 Jepsen P, Andersen MW, Villadsen GE, Ott P, Vilstrup H. Time-trends in incidence and prognosis of hepatocellular carcinoma in Denmark: A nationwide register-based cohort study. Liver Int 2017;37:871-8. [DOI: 10.1111/liv.13340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
224 Kang HJ, Kim YI, Kim HC, Jae HJ, Hur S, Chung JW. Does Establishing a Safety Margin Reduce Local Recurrence in Subsegmental Transarterial Chemoembolization for Small Nodular Hepatocellular Carcinomas? Korean J Radiol 2015;16:1068-78. [PMID: 26357501 DOI: 10.3348/kjr.2015.16.5.1068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
225 Ma XL, Gao XH, Gong ZJ, Wu J, Tian L, Zhang CY, Zhou Y, Sun YF, Hu B, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget 2016;7:70654-68. [PMID: 27683106 DOI: 10.18632/oncotarget.12203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
226 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 63] [Article Influence: 31.0] [Reference Citation Analysis]
227 Hedenstierna M, Nangarhari A, Weiland O, Aleman S. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. Clin Infect Dis 2016;63:723-9. [DOI: 10.1093/cid/ciw362] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
228 Liu Q, Tu K, Zhang H, Zheng X, Yao Y, Liu Q. TPX2 as a novel prognostic biomarker for hepatocellular carcinoma. Hepatol Res. 2015;45:906-918. [PMID: 25263743 DOI: 10.1111/hepr.12428] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
229 Makino Y, Imai Y, Igura T, Hori M, Fukuda K, Sawai Y, Kogita S, Ohama H, Matsumoto Y, Nakahara M, Zushi S, Kurokawa M, Isotani K, Takamura M, Fujita N, Murakami T. Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression: Evaluation of RFA using CT fusion image. Hepatol Res 2013;43:950-8. [DOI: 10.1111/hepr.12049] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
230 Rosenkrantz AB, Campbell N, Wehrli N, Triolo MJ, Kim S. New OPTN/UNOS Classification System for Nodules in Cirrhotic Livers Detected with MR Imaging: Effect on Hepatocellular Carcinoma Detection and Transplantation Allocation. Radiology 2015;274:426-33. [DOI: 10.1148/radiol.14140069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
231 Wang L, Ke J, Wang C, Li Y, Wu G, Ding Q, Luo Q, Cai R, Lv P, Song T, Xiong S. Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. Integr Cancer Ther 2020;19:1534735420942587. [PMID: 32787468 DOI: 10.1177/1534735420942587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
232 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016;22:262-274. [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 56] [Article Influence: 16.5] [Reference Citation Analysis]
233 McGowan CE, Edwards TP, Luong MU, Hayashi PH. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol 2015;13:799-804. [PMID: 25117773 DOI: 10.1016/j.cgh.2014.07.056] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
234 Chon YE, Kim DJ, Kim SG, Kim IH, Bae SH, Hwang SG, Heo J, Jang JW, Lee BS, Kim HJ, Jun DW, Kim KM, Chung WJ, Choi MS, Jang JY, Yim HJ, Tak WY, Yoon KT, Park JY, Han KH, Suk KT, Lee HW, Jang BK, Ahn SH. An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study. Medicine (Baltimore) 2016;95:e3026. [PMID: 27057828 DOI: 10.1097/MD.0000000000003026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
235 Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol 2017;23:42-50. [PMID: 28263954 DOI: 10.3350/cmh.2016.0058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
236 Sarfi M, Abbastabar M, Khalili E. Long noncoding RNAs biomarker-based cancer assessment. J Cell Physiol 2019;234:16971-86. [PMID: 30835829 DOI: 10.1002/jcp.28417] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 19.0] [Reference Citation Analysis]
237 Díaz-González Á, Sapena V, Boix L, Brunet M, Torres F, LLarch N, Samper E, Millán O, Corominas J, Iserte G, Sanduzzi-Zamparelli M, da Fonseca LG, Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M. Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. Liver Int 2020;40:2476-88. [PMID: 33021346 DOI: 10.1111/liv.14587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Abdelghany AM, Rezk NS, Osman MM, Hamid AI, Al-Breedy AM, Abdelsattar HA. Using Lamin B1 mRNA for the early diagnosis of hepatocellular carcinoma: a cross-sectional diagnostic accuracy study. F1000Res 2018;7:1339. [PMID: 30467522 DOI: 10.12688/f1000research.14795.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
239 Chen J, Wu G, Li Y. Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. Dis Markers. 2018;2018:8906023. [PMID: 30402170 DOI: 10.1155/2018/8906023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
240 Jiang Z, Shen L, Wang S, Wu S, Hu Y, Guo J, Fu L. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Med 2019;8:7278-87. [PMID: 31595711 DOI: 10.1002/cam4.2584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
241 Liang L, Chen TH, Li C, Xing H, Han J, Wang MD, Zhang H, Lau WY, Wu MC, Shen F, Yang T. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018;20:1119-1129. [PMID: 30056066 DOI: 10.1016/j.hpb.2018.06.1804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
242 Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH, Wang CC, Kuo SF, Liu CH, Chen PJ. Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. Medicine (Baltimore). 2016;95:e2995. [PMID: 26962809 DOI: 10.1097/md.0000000000002995] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
243 Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y. Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1272-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017;2:98. [PMID: 29264436 DOI: 10.21037/tgh.2017.11.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
245 Carrion AF, Aye L, Martin P. Patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2013;7:571-579. [PMID: 23985006 DOI: 10.1586/17474124.2013.824701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
246 Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20:4160-4166. [PMID: 24764654 DOI: 10.3748/wjg.v20.i15.4160] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
247 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50. [PMID: 25247563 DOI: 10.1148/radiol.14132362] [Cited by in Crossref: 256] [Cited by in F6Publishing: 197] [Article Influence: 42.7] [Reference Citation Analysis]
248 Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria. PLoS One 2020;15:e0242344. [PMID: 33186378 DOI: 10.1371/journal.pone.0242344] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Shim JH, Han S, Shin YM, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma. J Magn Reson Imaging 2015;41:1115-23. [PMID: 24841479 DOI: 10.1002/jmri.24660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
250 Fan L, Xiao Q, Chen Y, Chen G, Duan J, Tao W. Pekinenin E Inhibits the Growth of Hepatocellular Carcinoma by Promoting Endoplasmic Reticulum Stress Mediated Cell Death. Front Pharmacol 2017;8:424. [PMID: 28706487 DOI: 10.3389/fphar.2017.00424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
251 Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: local control rate and risk of peritoneal seeding at long-term follow-up. Clin Radiol 2013;68:e641-51. [PMID: 23973161 DOI: 10.1016/j.crad.2013.07.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
252 Tsuruoka M, Inoue J, Kakazu E, Ninomiya M, Iwata T, Sano A, Masamune A. Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Intern Med 2020;59:2255-60. [PMID: 32522926 DOI: 10.2169/internalmedicine.4787-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1611] [Article Influence: 321.3] [Reference Citation Analysis]
254 Park JH, Yoon SM, Lim YS, Kim SY, Shim JH, Kim KM, Lee HC, Cho B, Park G, Kim JH. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:1638-1642. [PMID: 23621519 DOI: 10.1111/jgh.12249] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
255 Murray LJ, Dawson LA. Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Semin Radiat Oncol. 2017;27:247-255. [PMID: 28577832 DOI: 10.1016/j.semradonc.2017.02.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
256 Shin J, Yu JH, Jin YJ, Suh YJ, Kim DH, Byun S, Lee JW. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. Medicine (Baltimore) 2019;98:e16150. [PMID: 31348228 DOI: 10.1097/MD.0000000000016150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
257 Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, Bai W, Dong Z, Lu Y, Zeng Z, Lou M, Wang H, Gao X, Chang X, An L, Qu J, Li J, Yang Y. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61:1579-1590. [PMID: 25284802 DOI: 10.1002/hep.27548] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 19.2] [Reference Citation Analysis]
258 Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2  cm in a Propensity Score Model. Ann Surg 2016;263:538-45. [PMID: 25775062 DOI: 10.1097/SLA.0000000000001178] [Cited by in Crossref: 86] [Cited by in F6Publishing: 46] [Article Influence: 17.2] [Reference Citation Analysis]
259 Kim JH, Kang SH, Lee M, Choi HS, Jun BG, Kim TS, Choi DH, Suk KT, Kim MY, Kim YD, Cheon GJ, Baik SK, Kim DJ. Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study. J Gastroenterol Hepatol 2020;35:1795-803. [PMID: 32222111 DOI: 10.1111/jgh.15046] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015;367:1-11. [DOI: 10.1016/j.canlet.2015.06.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 18.5] [Reference Citation Analysis]
261 Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016;34:160-167. [PMID: 27730805 DOI: 10.3857/roj.2016.01970] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
262 Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol. 2015;7:980-992. [PMID: 25954480 DOI: 10.4254/wjh.v7.i7.980] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
263 Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, Bae YS, Kim YJ. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76. [PMID: 26657650 DOI: 10.1038/bjc.2015.430] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
264 Reig M, Berzigotti A, Bruix J. If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection? Liver Int 2013;33:1454-6. [PMID: 24099263 DOI: 10.1111/liv.12273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Khoury T, Massarwa M, Hazou W, Daher S, Hakimian D, Benson AA, Ashqar T, Mahamid M, Yaari S. Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Cancer 2019;50:759-62. [PMID: 30043228 DOI: 10.1007/s12029-018-0149-5] [Reference Citation Analysis]
266 Berry K, Ioannou GN. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?: Liver Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation 2012;12:706-17. [DOI: 10.1111/j.1600-6143.2011.03853.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
267 Jin YJ, Lee D, Chung YH, Kim JA, Kim SE, Lee YS, Shin ES, Ryu SH, Jang MK, Lee JE, Park NH. Tumor Necrosis Factor-Alpha Gene Polymorphism Associated With Development of Hepatitis B Virus-associated Hepatocellular Carcinoma. J Clin Gastroenterol 2015;49:e76-81. [PMID: 25319734 DOI: 10.1097/MCG.0000000000000261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
268 Kim JS, Choi GH, Jung Y, Kim KM, Jang SJ, Yu ES, Lee HC. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. J Cancer Res Clin Oncol 2018;144:1487-501. [PMID: 29858683 DOI: 10.1007/s00432-018-2672-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
269 Jia F, Wu B, Yan R, Li L, Wang K, Han D. Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization. J Magn Reson Imaging 2020;52:1657-67. [PMID: 32424881 DOI: 10.1002/jmri.27189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
270 Chan LS, Sze DY, Poultsides GA, Louie JD, Abdelrazek Mohammed MA, Wang DS. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma. Cardiovasc Intervent Radiol 2017;40:1383-91. [DOI: 10.1007/s00270-017-1648-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
271 Xu L, Zhou DS, Zhao J, Spolverato G, Zhang YJ, Li SP, Chen MS, Pawlik TM. Long-term therapy with sorafenib is associated with pancreatic atrophy. J Surg Res 2015;199:314-21. [PMID: 26115806 DOI: 10.1016/j.jss.2015.04.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
272 Lin L, Xiang X, Su S, Liu S, Xiong Y, Ma H, Yuan G, Nie D, Tang G. Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma. Front Chem 2021;9:630452. [PMID: 33937189 DOI: 10.3389/fchem.2021.630452] [Reference Citation Analysis]
273 Guo H, Wu T, Lu Q, Li M, Guo JY, Shen Y, Wu Z, Nan KJ, Lv Y, Zhang XF. Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages. Cancer Manag Res 2018;10:361-9. [PMID: 29503583 DOI: 10.2147/CMAR.S152707] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
274 Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119:1042-1049. [PMID: 23132335 DOI: 10.1002/cncr.27859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
275 David D, Raghavendran A, Goel A, Bharath Kumar C, Kodiatte TA, Burad D, Abraham P, Ramakrishna B, Joseph P, Ramachandran J, Eapen CE. Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India. Indian J Gastroenterol 2017;36:373-9. [PMID: 28975595 DOI: 10.1007/s12664-017-0785-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
276 Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020;44:247-257. [PMID: 31559485 DOI: 10.1007/s00268-019-05197-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Stefansdottir J, Christensen E, Schiødt FV. Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience. Scandinavian Journal of Gastroenterology 2017;52:768-72. [DOI: 10.1080/00365521.2017.1304985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Hung CH, Chiu YC, Hu TH, Chen CH, Lu SN, Huang CM, Wang JH, Lee CM. Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C. Transl Oncol 2014;7:503-7. [PMID: 24894441 DOI: 10.1016/j.tranon.2014.05.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
279 de Mattos ÂZ, de Mattos AA. Hepatocellular carcinoma: To resect or to transplant? Hepatology 2016;63:344-5. [PMID: 26033524 DOI: 10.1002/hep.27919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38:129-134. [PMID: 24870698 DOI: 10.1007/s00270-014-0907-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
281 Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344-353. [PMID: 26340708 DOI: 10.3109/00365521.2015.1082190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
282 Akamatsu N, Sugawara Y, Kokudo N. Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol. 2014;6:626-631. [PMID: 25276278 DOI: 10.4254/wjh.v6.i9.626] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
283 Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
284 Allampati S, Mullen KD. Long-Term Management of Alcoholic Liver Disease. Clinics in Liver Disease 2016;20:551-62. [DOI: 10.1016/j.cld.2016.02.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
285 Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS One 2016;11:e0146456. [PMID: 26745625 DOI: 10.1371/journal.pone.0146456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
286 Kluger MD, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, Luciani A, Van Nhieu JT, Azoulay D, Cherqui D. Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62:1131-1140. [PMID: 25529622 DOI: 10.1016/j.jhep.2014.12.018] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
287 Xu X, Liu C, Qu K, Song Y, Zhang P, Zhang Y. Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2014;13:234-41. [DOI: 10.1016/s1499-3872(14)60037-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
288 Antonelli G, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, Biondetti P, Pellicelli AM, Miglioresi L, Marchetti P, Lampertico P, Marignani M. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterol J 2018;6:1039-48. [PMID: 30228892 DOI: 10.1177/2050640618781188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
289 Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One. 2014;9:e96620. [PMID: 24817002 DOI: 10.1371/journal.pone.0096620] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
290 Suh SW, Choi YS. Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma. Yonsei Med J 2017;58:737-42. [PMID: 28540985 DOI: 10.3349/ymj.2017.58.4.737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
291 Lin ZY, Wang JH, Yeh ML, Huang CI, Kee KM, Yen YH, Chen SC, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL. Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. Kaohsiung J Med Sci 2020;36:750-6. [PMID: 32349190 DOI: 10.1002/kjm2.12221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Toyoda H, Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T, Tanaka J. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. Liver Int 2018;38:2260-8. [PMID: 29981527 DOI: 10.1111/liv.13927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
293 Campos-Correia D, Cruz J, Matos AP, Figueiredo F, Ramalho M. Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: An illustrative review. World J Radiol 2018;10:9-23. [PMID: 29507710 DOI: 10.4329/wjr.v10.i2.9] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
294 Kircher A, Bongartz G, Merkle EM, Zech CJ. [Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria]. Radiologe 2014;54:664-72. [PMID: 25047522 DOI: 10.1007/s00117-014-2652-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
295 Davis CI, Gu X, Kiefer RM, Ralle M, Gade TP, Brady DC. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics 2020;12:1995-2008. [PMID: 33146201 DOI: 10.1039/d0mt00156b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Huang Z, Zhang P, Wang H, Yan L, Wang W. Comparing outcomes of two vascular inflow occlusion techniques and treatment without vascular occlusion during major hepatectomy in patients with Hepatitis B-related hepatocellular carcinoma. PLoS One 2014;9:e107303. [PMID: 25203056 DOI: 10.1371/journal.pone.0107303] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
297 Haubold J, Reinboldt MP, Wetter A, Li Y, Ludwig JM, Lange C, Wedemeyer H, Schotten C, Umutlu L, Theysohn J. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. Rofo 2020;192:862-9. [PMID: 32131109 DOI: 10.1055/a-1111-9955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Gao J, Zhou Y, Zhang Q, Kong J, Ke S, Ding X, Wang S, Sun W. Early Laparoscopic Radiofrequency Ablation for Spontaneous Rupture of Hepatocellular Carcinoma. Journal of Laparoendoscopic & Advanced Surgical Techniques 2016;26:560-6. [DOI: 10.1089/lap.2016.0118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
299 Sinn DH, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Pre-s mutation is a significant risk factor for hepatocellular carcinoma development: a long-term retrospective cohort study. Dig Dis Sci. 2013;58:751-758. [PMID: 23053886 DOI: 10.1007/s10620-012-2408-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
300 Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett 2019;459:156-67. [PMID: 31181320 DOI: 10.1016/j.canlet.2019.114429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
301 Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3:57-59. [PMID: 26998221 DOI: 10.2217/hep.15.41] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
302 Azer SA, Azer S. Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open 2016;6:e009889. [PMID: 26857105 DOI: 10.1136/bmjopen-2015-009889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
303 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
304 Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017;123:751-8. [PMID: 27911488 DOI: 10.1002/cncr.30462] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
305 Huang PY, Wang CC, Lin CC, Lu SN, Wang JH, Hung CH, Kee KM, Chen CH, Chen KD, Hu TH, Tsai MC. Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. J Clin Med. 2019;8. [PMID: 31614976 DOI: 10.3390/jcm8101676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
306 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
307 Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 2018;289:816-30. [PMID: 30251931 DOI: 10.1148/radiol.2018181494] [Cited by in Crossref: 212] [Cited by in F6Publishing: 177] [Article Influence: 70.7] [Reference Citation Analysis]
308 Zheng H, Chen T, Li C, Xu C, Ding C, Chen J, Ju S, Zhang Z, Liang Z, Cui Z, Zhao J. A circular RNA hsa_circ_0079929 inhibits tumor growth in hepatocellular carcinoma. Cancer Manag Res 2019;11:443-54. [PMID: 30655696 DOI: 10.2147/CMAR.S189338] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
309 Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol 2017;29:706-15. [PMID: 28195873 DOI: 10.1097/MEG.0000000000000852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
310 Wang Z, Chang Z, Lu M, Shao D, Yue J, Yang D, Li M, Dong WF. Janus Silver/Silica Nanoplatforms for Light-Activated Liver Cancer Chemo/Photothermal Therapy. ACS Appl Mater Interfaces 2017;9:30306-17. [PMID: 28836433 DOI: 10.1021/acsami.7b06446] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
311 Tian X, Dai Y, Wang DQ, Zhang L, Sui CG, Meng FD, Jiang SY, Liu YP, Jiang YH. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther 2015;9:4431-40. [PMID: 26309396 DOI: 10.2147/DDDT.S86629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
312 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
313 Parikh ND, Singal AG, Hutton DW. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma: Regorafenib Cost Effectiveness. Cancer 2017;123:3725-31. [DOI: 10.1002/cncr.30863] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
314 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
315 Boulin M, Schmitt A, Delhom E, Cercueil JP, Wendremaire M, Imbs DC, Fohlen A, Panaro F, Herrero A, Denys A, Guiu B. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Eur Radiol. 2016;26:601-609. [PMID: 26060065 DOI: 10.1007/s00330-015-3855-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
316 Bao T, Ke Y, Wang Y, Wang W, Li Y, Wang Y, Kui X, Zhou Q, Zhou H, Zhang C, Zhou D, Wang L, Xiao C. Taraxasterol suppresses the growth of human liver cancer by upregulating Hint1 expression. J Mol Med 2018;96:661-72. [DOI: 10.1007/s00109-018-1652-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
317 Dokmak S, Elkrief L, Belghiti J. Auxiliary liver transplantation with a small deceased liver graft for cirrhotic liver complicated by hepatocellular carcinoma. Transpl Int 2013;26:e102-4. [DOI: 10.1111/tri.12173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
318 Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y. Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. Liver Int. 2013;33:762-770. [PMID: 23445409 DOI: 10.1111/liv.12130] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
319 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
320 Zhao W, Shang X, Zhao L, Yao G, Sun Z, Huang X, Song S. Bioactivity-guided isolation of β-Carboline alkaloids with potential anti-hepatoma effect from Picrasma quassioides (D. Don) Benn. Fitoterapia 2018;130:66-72. [DOI: 10.1016/j.fitote.2018.08.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
321 Mu L, Sun L, Pan T, Lyu N, Li S, Li X, Wang J, Xie Q, Deng H, Zheng L, Peng J, Shen L, Fan W, Wu P, Zhao M. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperthermia. 2018;34:59-67. [PMID: 28540809 DOI: 10.1080/02656736.2017.1318332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
322 Zhang N, Gu J, Yin L, Wu J, Du MY, Ding K, Huang T, He X. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget 2016;7:81389-401. [PMID: 27835609 DOI: 10.18632/oncotarget.13232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
323 Nischalke HD, Lutz P, Krämer B, Söhne J, Müller T, Rosendahl J, Fischer J, Berg T, Hittatiya K, Fischer H, Soyka M, Semmo N, Nattermann J, Sauerbruch T, Strassburg CP, Stickel F, Spengler U. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. Journal of Hepatology 2014;61:1073-9. [DOI: 10.1016/j.jhep.2014.06.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
324 Lachenmayer A, Tinguely P, Maurer MH, Frehner L, Knöpfli M, Peterhans M, Weber S, Dufour J, Candinas D, Banz V. Stereotactic image‐guided microwave ablation of hepatocellular carcinoma using a computer‐assisted navigation system. Liver Int 2019;39:1975-85. [DOI: 10.1111/liv.14187] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
325 Rahman WT, Hussain HK, Parikh ND, Davenport MS. Reinterpretation of Outside Hospital MRI Abdomen Examinations in Patients With Cirrhosis: Is the OPTN Mandate Necessary? American Journal of Roentgenology 2016;207:782-8. [DOI: 10.2214/ajr.16.16209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.4] [Reference Citation Analysis]
326 Ma J, Siegel RL, Islami F, Jemal A. Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015. Cancer 2019;125:2089-98. [PMID: 30957228 DOI: 10.1002/cncr.32023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
327 Chen CL, Chang WC, Yi CH, Hung JS, Liu TT, Lei WY, Hsu CS. Association of coffee consumption and liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B: A 5-year population-based cohort study. J Formos Med Assoc 2019;118:628-35. [PMID: 30122312 DOI: 10.1016/j.jfma.2018.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
328 Xiao YS, Gao Q, Xu XN, Li YW, Ju MJ, Cai MY, Dai CX, Hu J, Qiu SJ, Zhou J, Fan J. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection. PLoS One 2013;8:e70345. [PMID: 23940564 DOI: 10.1371/journal.pone.0070345] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
329 Hyun D, Cho SK, Shin SW, Park KB, Lee SY, Park HS, Do YS. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes. Acta Radiol 2018;59:773-81. [PMID: 29034691 DOI: 10.1177/0284185117735349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
330 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
331 Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett 2017;13:984-92. [PMID: 28356989 DOI: 10.3892/ol.2016.5525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
332 Lin L, Chen G, Chen Z, Lu J, Zhu W, Zhong J, Peng F, Huang A. Prognostic value of tumor stromal collagen features in patients with hepatocellular carcinoma revealed by second-harmonic generation microscopy. Exp Mol Pathol 2020;116:104513. [PMID: 32735795 DOI: 10.1016/j.yexmp.2020.104513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Yamashita YI, Imai K, Yusa T, Nakao Y, Kitano Y, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, Aishima S, Maehara Y, Baba H. Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments. Ann Gastroenterol Surg 2018;2:197-203. [PMID: 29863190 DOI: 10.1002/ags3.12057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
334 Sánchez-Delgado J, Calzado S, de Haro C, Mas M, Miquel M, Casas M, Vergara M, Dalmau B, Gil M. [Long survival after resection of cranial metastases from hepatocellular carcinoma. Case report and review of the literature]. Gastroenterol Hepatol 2012;35:12-6. [PMID: 22177938 DOI: 10.1016/j.gastrohep.2011.11.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
335 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
336 Pauwels X, Azahaf M, Lassailly G, Sergent G, Buob D, Truant S, Boleslawski E, Louvet A, Gnemmi V, Canva V, Mathurin P, Pruvot F, Leteurtre E, Ernst O, Dharancy S. Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. Cardiovasc Intervent Radiol 2015;38:685-92. [DOI: 10.1007/s00270-014-0967-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
337 Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology 2016;64:1136-47. [PMID: 27348075 DOI: 10.1002/hep.28702] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
338 Xing H, Yan C, Cheng L, Wang N, Dai S, Yuan J, Lu W, Wang Z, Han J, Zheng Y, Yang T. Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. Tumor Biol 2016;37:15447-56. [DOI: 10.1007/s13277-016-5443-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
339 Chen J, Luo Y, Cai S, Ji W, Yao M, Jiang K, Dong J. Ultrasound-guided radiofrequency ablation of the segmental Glissonian pedicle: A new technique for anatomic liver resection. Surgery 2016;159:802-9. [DOI: 10.1016/j.surg.2015.09.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
340 Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37:91-7. [PMID: 23094860 DOI: 10.1111/apt.12098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
341 Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett 2018;16:7123-30. [PMID: 30546447 DOI: 10.3892/ol.2018.9547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
342 Kawaguchi Y, Lillemoe HA, Vauthey JN. Surgical Resection: Old Dog, Any New Tricks? Clin Liver Dis 2020;24:637-55. [PMID: 33012450 DOI: 10.1016/j.cld.2020.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
343 Zhao B, Lu J, Yin J, Liu H, Guo X, Yang Y, Ge N, Zhu Y, Zhang H, Xing J. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int. 2012;32:1451-1459. [PMID: 22809120 DOI: 10.1111/j.1478-3231.2012.02849.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
344 Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK. Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study. Antivir Ther 2019;24:567-79. [PMID: 31799942 DOI: 10.3851/IMP3338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Park YS, Lee CH, Kim JH, Kim IS, Kiefer B, Seo TS, Kim KA, Park CM. Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: a preliminary result. MagnReson Imaging. 2014;32:638-646. [PMID: 24703575 DOI: 10.1016/j.mri.2014.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
346 Kim HA, Kim KA, Choi JI, Lee JM, Lee CH, Kang TW, Ku YM, Lee SL, Park YS, Yoon JH, Kim SH, Choi MH. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer 2017;17:877. [PMID: 29268722 DOI: 10.1186/s12885-017-3819-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
347 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
348 Lintia-Gaultier A, Perret C, Ansquer C, Eugène T, Kraeber-Bodéré F, Frampas E. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years’ experience. Nucl Med Commun. 2013;34:674-681. [PMID: 23587835 DOI: 10.1097/mnm.0b013e32836141a0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
349 Li M, Fu S, Zhu Y, Liu Z, Chen S, Lu L, Liang C. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget 2016;7:13248-59. [PMID: 26910890 DOI: 10.18632/oncotarget.7467] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
350 Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, Gan YH, Chen Y, Zhang JB, Xue TC, Chen RX, Xia JL, Zhang BH, Ye SL, Wang YH, Ren ZG. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol 2015;21:3970-7. [PMID: 25852283 DOI: 10.3748/wjg.v21.i13.3970] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
351 Regan-Fendt K, Li D, Reyes R, Yu L, Wani NA, Hu P, Jacob ST, Ghoshal K, Payne PRO, Motiwala T. Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2730. [PMID: 32977582 DOI: 10.3390/cancers12102730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
352 Arslanoglu A, Seyal AR, Sodagari F, Sahin A, Miller FH, Salem R, Yaghmai V. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. American Journal of Roentgenology 2016;207:W88-98. [DOI: 10.2214/ajr.15.15490] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 3.4] [Reference Citation Analysis]
353 Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8165. [PMID: 33142892 DOI: 10.3390/ijms21218165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
354 Liu W, Zhou J, Sun Y, Zhang L, Xing B. Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. J Gastrointest Surg 2015;19:1271-80. [DOI: 10.1007/s11605-015-2811-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
355 Ye W, Li J, Fang G, Cai X, Zhang Y, Zhou C, Chen L, Yang W. Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma: Association between clinicopathological features and prognosis. Oncol Lett 2018;15:7255-64. [PMID: 29731884 DOI: 10.3892/ol.2018.8208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
356 Gilabert M, Raoul JL. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. J Hepatocell Carcinoma 2018;5:91-8. [PMID: 30464931 DOI: 10.2147/JHC.S157413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
357 Tanabe M, Kanki A, Wolfson T, Costa EA, Mamidipalli A, Ferreira MP, Santillan C, Middleton MS, Gamst AC, Kono Y, Kuo A, Sirlin CB. Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging. Radiology. 2016;281:129-139. [PMID: 27115054 DOI: 10.1148/radiol.2016152173] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 11.4] [Reference Citation Analysis]
358 Lee CH, Hsieh SY, Lin JL, Liu MS, Yen TH. Hepatocellular carcinoma in patients with chronic kidney disease. World J Gastroenterol 2013;19:2466-72. [PMID: 23674847 DOI: 10.3748/wjg.v19.i16.2466] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
359 Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol 2017;23:2448-52. [PMID: 28428725 DOI: 10.3748/wjg.v23.i13.2448] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
360 Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, Regnault H, Amaddeo G, Itti E, Luciani A, Kobeiter H, Tacher V. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44. [PMID: 33012693 DOI: 10.1016/j.diii.2020.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
361 Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018;13:e0207132. [PMID: 30408106 DOI: 10.1371/journal.pone.0207132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
362 Namisaki T, Schaeffeler E, Fukui H, Yoshiji H, Nakajima Y, Fritz P, Schwab M, Nies AT. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab Dispos. 2014;42:2033-2040. [PMID: 25231932 DOI: 10.1124/dmd.114.059832] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
363 Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, Endo M, Itoh Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-86. [PMID: 29234631 DOI: 10.1159/000473887] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
364 Quaia E, De Paoli L, Pizzolato R, Angileri R, Pantano E, Degrassi F, Ukmar M, Cova MA. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase. AJR Am J Roentgenol. 2013;200:553-562. [PMID: 23436844 DOI: 10.2214/ajr.12.8818] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
365 Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J, Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol. 2012;199:1018-1025. [PMID: 23096174 DOI: 10.2214/ajr.12.8632] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
366 Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 2013;8:e68193. [PMID: 23874536 DOI: 10.137/journal.pone.0068193] [Reference Citation Analysis]
367 Famularo S, Donadon M, Cipriani F, Ardito F, Carissimi F, Perri P, Iaria M, Dominioni T, Zanello M, Conci S, Molfino S, LaBarba G, Ferrari C, Germani P, Patauner S, Pinotti E, Lodo E, Garatti M, Sciannamea I, Troci A, Conticchio M, Floridi A, Chiarelli M, Fumagalli L, Memeo R, Crespi M, Antonucci A, Zimmitti G, Zanus G, Zago M, Frena A, Tarchi P, Griseri G, Ercolani G, Baiocchi GL, Ruzzenente A, Jovine E, Maestri M, DallaValle R, Grazi GL, Giuliante F, Aldrighetti L, Torzilli G, Romano F;  HE. RC.O.LE.S. Group. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. Updates Surg. 2020;72:399-411. [PMID: 32170630 DOI: 10.1007/s13304-020-00733-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
368 Wang J, Li Y, Ma Q, Huang J. miR‑378 in combination with ultrasonic irradiation and SonoVue microbubbles transfection inhibits hepatoma cell growth. Mol Med Rep 2020;21:2493-501. [PMID: 32236628 DOI: 10.3892/mmr.2020.11045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014;20:12581-7. [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
370 Imada S, Ishiyama K, Ide K, Kobayashi T, Amano H, Tashiro H, Arihiro K, Aikata H, Chayama K, Ohdan H. Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma. World J Surg Oncol 2013;11:177. [PMID: 23915104 DOI: 10.1186/1477-7819-11-177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
371 Miao Y, Zhang Y, Yin L. Trends in hepatocellular carcinoma research from 2008 to 2017: a bibliometric analysis. PeerJ 2018;6:e5477. [PMID: 30128213 DOI: 10.7717/peerj.5477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
372 Zhang QB, Zhang XG, Jiang RD, Hu CX, Sun D, Ran L, Zhang ZL. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. Int J Hyperthermia 2017;33:255-62. [PMID: 27817240 DOI: 10.1080/02656736.2016.1257824] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
373 Hu KS, Tang B, Yuan J, Lu SX, Li M, Chen RX, Zhang L, Ren ZG, Yin X. A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2019;34:1984-91. [PMID: 30932246 DOI: 10.1111/jgh.14673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
374 Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, Kim WR. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018;68:78-88. [PMID: 29023828 DOI: 10.1002/hep.29594] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
375 Lewis S, Roayaie S, Ward SC, Shyknevsky I, Jibara G, Taouli B. Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. AJR Am J Roentgenol. 2013;200:W610-W616. [PMID: 23701091 DOI: 10.2214/ajr.12.9151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
376 Koppe C, Verheugd P, Gautheron J, Reisinger F, Kreggenwinkel K, Roderburg C, Quagliata L, Terracciano L, Gassler N, Tolba RH, Boege Y, Weber A, Karin M, Luedde M, Neumann UP, Weiskirchen R, Tacke F, Vucur M, Trautwein C, Lüscher B, Preisinger C, Heikenwalder M, Luedde T. IκB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1. Hepatology 2016;64:1217-31. [PMID: 27396433 DOI: 10.1002/hep.28723] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
377 Lin ZX, Ruan DY, Li Y, Wu DH, Ma XK, Chen J, Chen ZH, Li X, Wang TT, Lin Q. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection. World J Gastroenterol. 2015;21:10898-10906. [PMID: 26478681 DOI: 10.3748/wjg.v21.i38.10898] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
378 Pregler B, Beyer LP, Teufel A, Niessen C, Stroszczynski C, Brodoefel H, Wiggermann P. Low Tube Voltage Liver MDCT with Sinogram-Affirmed Iterative Reconstructions for the Detection of Hepatocellular Carcinoma. Sci Rep 2017;7:9460. [PMID: 28842662 DOI: 10.1038/s41598-017-10095-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
379 Wu C, Hsu Y, Ho HJ, Chen Y, Lee T, Lin J. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut 2016;65:693-701. [DOI: 10.1136/gutjnl-2014-308786] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
380 Beaton L, Dunne EM, Yeung R, Rackley T, Weber B, Mar C, Yong-Hing CJ, Yoshida EM, DeVries K, Lee R, Duzenli C, Loewen SK, Liu M, Schellenberg D, Ma R. Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study. Clin Oncol (R Coll Radiol) 2020;32:423-32. [PMID: 32093876 DOI: 10.1016/j.clon.2020.01.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
381 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:401-20. [DOI: 10.1016/j.cld.2015.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
382 Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015;8:609. [PMID: 26502722 DOI: 10.1186/s13104-015-1565-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
383 Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, Giannini EG, Farinati F, Ciccarese F, Andreone P, Bernardi M, Trevisani F. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer 2015;112:69-76. [PMID: 25314061 DOI: 10.1038/bjc.2014.536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
384 Karass M, Grossniklaus E, Seoud T, Kamel R, Teniola O, Oprea G, Goldstein DA, Jain S. Metastatic colorectal cancer in a cirrhotic liver with synchronous hepatocellular carcinoma. Ann Transl Med 2015;3:321. [PMID: 26697481 DOI: 10.3978/j.issn.2305-5839.2015.11.28] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
385 Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD. Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. J Clin Gastroenterol 2016;50:258-65. [PMID: 26352107 DOI: 10.1097/MCG.0000000000000411] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
386 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 884] [Article Influence: 526.7] [Reference Citation Analysis]
387 Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, Tengg-kobligk HV, Candinas D, Dufour J. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. Annals of Hepatology 2016;15:82-90. [DOI: 10.5604/16652681.1184233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
388 Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14. [PMID: 31006227 DOI: 10.14366/usg.18060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
389 Kwon HJ, Byun JH, Kim JY, Hong GS, Won HJ, Shin YM, Kim PN. Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images. Abdom Imaging. 2015;40:64-75. [PMID: 24997560 DOI: 10.1007/s00261-014-0188-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
390 Hassan MA, Kim WR, Li R, Smith CI, Fried MW, Sterling RK, Ghany MG, Wahed AS, Ganova-Raeva LM, Roberts LR, Lok ASF; Hepatitis B Research Network. Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. Am J Epidemiol 2017;186:356-66. [PMID: 28525625 DOI: 10.1093/aje/kwx064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
391 Dou C, Zhou Z, Xu Q, Liu Z, Zeng Y, Wang Y, Li Q, Wang L, Yang W, Liu Q, Tu K. Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway. Oncogene. 2019;38:1239-1255. [PMID: 30250300 DOI: 10.1038/s41388-018-0505-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
392 Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miura T, Tomonaga T, Yoshitomi H, Imazeki F, Takizawa H. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2012;421:837-843. [PMID: 22554520 DOI: 10.1016/j.bbrc.2012.04.099] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
393 Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, Chen J, Lin Q, Ma XK, Wen JY, Xie SD, Wu XY, Dong M. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9:2380-2388. [PMID: 30026834 DOI: 10.7150/jca.22925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
394 Neamatallah M, El-Bendary M, Elalfy H, Besheer T, El-Maksoud MA, Elhammady D, Abed S, Elegezy M, Kandeel L, Eldeib D, Mousa N, Abd El-Hafeez M, El-Gilany AH, Esmat G. Impact of Toll-like Receptors 2(TLR2) and TLR 4 Gene Variations on HCV Susceptibility, Response to Treatment and Development of Hepatocellular Carcinoma in Cirrhotic HCV Patients. Immunol Invest. 2020;49:462-476. [PMID: 31615295 DOI: 10.1080/08820139.2019.1673772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
395 Brock KK. Imaging and image-guided radiation therapy in liver cancer. Semin Radiat Oncol. 2011;21:247-255. [PMID: 21939853 DOI: 10.1016/j.semradonc.2011.05.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
396 Rustogi R, Horowitz J, Harmath C, Wang Y, Chalian H, Ganger DR, Chen ZE, Bolster BD, Shah S, Miller FH. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging. 2012;35:1356-1364. [PMID: 22246952 DOI: 10.1002/jmri.23585] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 10.1] [Reference Citation Analysis]
397 Cho HJ, Kim SS, Kang SY, Yang MJ, Noh CK, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY; Korean Liver Cancer Association. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status. Gut Liver 2019;13:557-68. [PMID: 31023007 DOI: 10.5009/gnl18444] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
398 He L, Zhang S, Liu X, Jiang Y, Wang X, Yang Z. HbA1c-Based Score Model for Predicting Death Risk in Patients with Hepatocellular Carcinoma and Type 2 Diabetes Mellitus. J Diabetes Res 2017;2017:3819502. [PMID: 28154829 DOI: 10.1155/2017/3819502] [Reference Citation Analysis]
399 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
400 Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013;45:510-515. [PMID: 23218990 DOI: 10.1016/j.dld.2012.10.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
401 Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. Journal of Hepatology 2012;56:464-73. [DOI: 10.1016/j.jhep.2011.07.012] [Cited by in Crossref: 173] [Cited by in F6Publishing: 171] [Article Influence: 19.2] [Reference Citation Analysis]
402 Zhang J, Qi YP, Ma N, Lu F, Gong WF, Chen B, Ma L, Zhong JH, Xiang BD, Li LQ. Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma. J Cancer. 2020;11:3400-3406. [PMID: 32231746 DOI: 10.7150/jca.41090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
403 Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8:16498-16506. [PMID: 28157705 DOI: 10.18632/oncotarget.14954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
404 Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64:2077-2088. [PMID: 27178646 DOI: 10.1002/hep.28643] [Cited by in Crossref: 148] [Cited by in F6Publishing: 132] [Article Influence: 29.6] [Reference Citation Analysis]
405 Wong TCL, Ng KKC, Fung JYY, Chan AAC, Cheung T, Chok KSH, Dai JWC, Lo C. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses. Ann Surg Oncol 2019;26:1454-62. [DOI: 10.1245/s10434-019-07206-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
406 Hsiao P, Hsieh KC, Chen YS, Hsu CC, Lo GH, Li YC, Hsieh PM, Lin HY, Wu TC, Yeh JH, Lin CW. Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e16074. [PMID: 31232945 DOI: 10.1097/MD.0000000000016074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
407 Zeng Q, Qiu J, Hong J, Li Y, Li S, Zou R, Huang P, Li B, Zheng Y, Lao X, Yuan Y. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis: . European Journal of Gastroenterology & Hepatology 2012;24:575-82. [DOI: 10.1097/meg.0b013e328351046a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
408 Manini MA, Sangiovanni A, Fornari F, Piscaglia F, Biolato M, Fanigliulo L, Ravaldi E, Grieco A, Colombo M. Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol. 2014;60:995-1001. [PMID: 24462368 DOI: 10.1016/j.jhep.2014.01.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
409 Abei M, Okumura T, Fukuda K, Hashimoto T, Araki M, Ishige K, Hyodo I, Kanemoto A, Numajiri H, Mizumoto M. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol. 2013;8:239. [PMID: 24131485 DOI: 10.1186/1748-717x-8-239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
410 Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Lee FY, Huo TI. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol 2013;20:2035-42. [PMID: 23306955 DOI: 10.1245/s10434-012-2847-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
411 Borgheresi A, Covey A, Yarmohammadi H, Boas FE, Ziv E, Getrajdman G, Erinjeri J, Jarnagin W, Harding JJ, D'Angelica M, Gonen M, Brown KT. Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. HPB (Oxford) 2020;22:588-94. [PMID: 31474455 DOI: 10.1016/j.hpb.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Hoehn RS, Hanseman DJ, Jernigan PL, Wima K, Ertel AE, Abbott DE, Shah SA; Cincinnati Research in Outcomes and Safety in Surgery (CROSS). Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford) 2015;17:747-52. [PMID: 26278321 DOI: 10.1111/hpb.12427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
413 Yu R, Ding S, Tan W, Tan S, Tan Z, Xiang S, Zhou Y, Mao Q, Deng G. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon. 2015;15:e28806. [PMID: 26300931 DOI: 10.5812/hepatmon.28806v2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
414 Jones PD, Diaz C, Wang D, Gonzalez-diaz J, Martin P, Kobetz E. The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population. Dig Dis Sci 2018;63:515-28. [DOI: 10.1007/s10620-017-4869-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
415 Noor MT, Tiwari M, Kumar R. Non-HFE iron overload as a surrogate marker of disease severity in patients of liver cirrhosis. Indian J Gastroenterol 2016;35:33-9. [PMID: 26873085 DOI: 10.1007/s12664-016-0623-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
416 Yu D, Shi X, Meng G, Chen J, Yan C, Jiang Y, Wei J, Ding Y. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget 2015;6:7619-31. [PMID: 25844758 DOI: 10.18632/oncotarget.3196] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 10.4] [Reference Citation Analysis]
417 Zhou D, Liu X, Wang X, Yan F, Wang P, Yan H, Jiang Y, Yang Z. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer 2021;21:246. [PMID: 33685417 DOI: 10.1186/s12885-021-07916-3] [Reference Citation Analysis]
418 Quaia E. State of the Art: LI-RADS for Contrast-enhanced US. Radiology 2019;293:4-14. [DOI: 10.1148/radiol.2019190005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
419 Sultanik P, Ginguay A, Vandame J, Popovici T, Meritet JF, Cynober L, Pol S, Bories PN. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J Viral Hepat 2017;24:80-5. [PMID: 27699936 DOI: 10.1111/jvh.12622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
420 Mao QG, Liang HQ, Yin YL, Tang JM, Yang JE, Wu CC, Chen Y, Zhang MY, Liu YY, Zheng XT, Zhuang LY, Chen SD. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2021;:101758. [PMID: 34303003 DOI: 10.1016/j.clinre.2021.101758] [Reference Citation Analysis]
421 Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013;5:186-194. [PMID: 24069511 DOI: 10.4251/wjgo.v5.i9.186] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
422 Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410. [PMID: 23469975 DOI: 10.2217/fon.13.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
423 Li L, Li B, Zhang M. HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore) 2019;98:e16308. [PMID: 31277172 DOI: 10.1097/MD.0000000000016308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
424 Liu PH, Hsu CY, Lee YH, Su CW, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) 2015;94:e1772. [PMID: 26469917 DOI: 10.1097/MD.0000000000001772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
425 Cheong JY, Shin HD, Cho SW, Kim YJ. Association of polymorphism in microRNA 604 with susceptibility to persistent hepatitis B virus infection and development of hepatocellular carcinoma. J Korean Med Sci. 2014;29:1523-1527. [PMID: 25408584 DOI: 10.3346/jkms.2014.29.11.1523] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
426 Garteiser P, Doblas S, Daire JL, Wagner M, Leitao H, Vilgrain V, Sinkus R, Van Beers BE. MR elastography of liver tumours: value of viscoelastic properties for tumour characterisation. Eur Radiol. 2012;22:2169-2177. [PMID: 22572989 DOI: 10.1007/s00330-012-2474-6] [Cited by in Crossref: 95] [Cited by in F6Publishing: 73] [Article Influence: 10.6] [Reference Citation Analysis]
427 Hassany M, Elsharkawy A, Maged A, Mehrez M, Asem N, Gomaa A, Mostafa Z, Abbas B, Soliman M, Esmat G. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol 2018;30:876-81. [PMID: 29727383 DOI: 10.1097/MEG.0000000000001152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
428 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
429 White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin Drug Discov 2015;10:427-39. [PMID: 25662396 DOI: 10.1517/17460441.2015.1006194] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
430 Montasser MF, Shaker MK, Albreedy AM, Montasser IF, El Dorry A. Risk factors for early intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma in Egyptian patients. J Dig Dis 2014;15:676-83. [PMID: 25214183 DOI: 10.1111/1751-2980.12190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
431 Hsu CY, Liu PH, Ho SY, Huang YH, Lee YH, Lee RC, Nagaria TS, Hou MC, Huo TI. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver Int 2018;38:1803-11. [PMID: 29608816 DOI: 10.1111/liv.13748] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
432 Liu P, Lee Y, Hsu C, Hsia C, Huang Y, Chiou Y, Lin H, Huo T. Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. J Gastrointest Surg 2014;18:1623-31. [DOI: 10.1007/s11605-014-2546-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
433 Güthle M, Dollinger MM. [Epidemiology and risk factors of hepatocellular carcinoma]. Radiologe 2014;54:654-9. [PMID: 24973122 DOI: 10.1007/s00117-014-2650-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
434 Abudawood M. Diabetes and cancer: A comprehensive review. J Res Med Sci 2019;24:94. [PMID: 31741666 DOI: 10.4103/jrms.JRMS_242_19] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
435 Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour JF. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J Hepatol 2017;67:876-8. [PMID: 28733219 DOI: 10.1016/j.jhep.2017.07.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
436 Yune Y, Kim S, Song I, Chun K. Comparative analysis of intraoperative radiofrequency ablation versus non-anatomical hepatic resection for small hepatocellular carcinoma: short-term result. Korean J Hepatobiliary Pancreat Surg 2015;19:173-80. [PMID: 26693237 DOI: 10.14701/kjhbps.2015.19.4.173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
437 Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol 2016;7:82-9. [PMID: 28840911 DOI: 10.1136/flgastro-2015-100617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
438 Higaki A, Ito K, Tamada T, Sone T, Kanki A, Noda Y, Yasokawa K, Yamamoto A. Prognosis of small hepatocellular nodules detected only at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging as hypointensity in cirrhosis or chronic hepatitis. Eur Radiol 2014;24:2476-81. [PMID: 25030460 DOI: 10.1007/s00330-014-3293-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
439 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
440 Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017;31:311-320. [PMID: 28774413 DOI: 10.1016/j.bpg.2017.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
441 Gao XH, Tian L, Wu J, Ma XL, Zhang CY, Zhou Y, Sun YF, Hu B, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Circulating CD14+ HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 2017;47:1061-1071. [PMID: 27764536 DOI: 10.1111/hepr.12831] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
442 Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013;19:634-645. [PMID: 23536495 DOI: 10.1002/lt.23652] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 13.0] [Reference Citation Analysis]
443 Wang F, Cui S, Wang F, Li F, Tang F, Zhang X, Gao Y, Lv H. Different scoring systems to predict 6-week mortality in cirrhosis patients with acute variceal bleeding: a retrospective analysis of 202 patients. Scandinavian Journal of Gastroenterology 2018;53:885-90. [DOI: 10.1080/00365521.2018.1481518] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
444 Boas FE, Kamaya A, Do B, Desser TS, Beaulieu CF, Vasanawala SS, Hwang GL, Sze DY. Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans. J Digit Imaging 2015;28:213-23. [PMID: 25183580 DOI: 10.1007/s10278-014-9725-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
445 DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:793-6. [PMID: 26171182 DOI: 10.3892/mco.2015.536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
446 Xu W, Rao Q, An Y, Li M, Zhang Z. Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma. PLoS One 2018;13:e0202763. [PMID: 30138346 DOI: 10.1371/journal.pone.0202763] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
447 Zou Q, Li J, Wu D, Yan Z, Wan X, Wang K, Shi L, Lau WY, Wu M, Shen F. Nomograms for Pre-operative and Post-operative Prediction of Long-Term Survival of Patients Who Underwent Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma. Ann Surg Oncol. 2016;23:2618-2626. [PMID: 26903045 DOI: 10.1245/s10434-016-5136-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
448 Yu J, Wang ZJ, Chen LH, Dong WZ. Diagnostic value of serum squamous cell carcinoma antigen for hepatocellular carcinoma: a systematic review and meta-analysis. Scand J Clin Lab Invest 2017;77:8-14. [PMID: 27762143 DOI: 10.1080/00365513.2016.1238504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
449 Zhang J, Yu Y, Li Y, Wei L. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016. Oncotarget 2017;8:75418-26. [PMID: 29088877 DOI: 10.18632/oncotarget.20049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
450 Jin Y, Wang K, Tian J. Preoperative Examination and Intraoperative Identification of Hepatocellular Carcinoma Using a Targeted Bimodal Imaging Probe. Bioconjugate Chem 2018;29:1475-84. [DOI: 10.1021/acs.bioconjchem.8b00161] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
451 Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:372-379. [PMID: 23927053 DOI: 10.1111/jgh.12350] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
452 Shin S, Lee SH, Lee M, Kim JH, Lee W, Lee HW, Park MS, Park S, Kim TS, Choi DH. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. Medicine (Baltimore) 2020;99:e19008. [PMID: 32118712 DOI: 10.1097/MD.0000000000019008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
453 Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, Mulcahy M, Baker T, Abecassis M, Sato KT, Caicedo JC, Fryer J, Hickey R, Hohlastos E, Lewandowski RJ, Salem R. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192-201. [PMID: 24691943 DOI: 10.1002/hep.27057] [Cited by in Crossref: 141] [Cited by in F6Publishing: 111] [Article Influence: 20.1] [Reference Citation Analysis]
454 Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, Morel P, Mentha G, Toso C. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol. 2014;60:969-974. [PMID: 24362073 DOI: 10.1016/j.jhep.2013.12.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
455 Ippolito D, Casiraghi AS, Talei Franzesi C, Bonaffini PA, Fior D, Sironi S. Intraobserver and Interobserver Agreement in the Evaluation of Tumor Vascularization With Computed Tomography Perfusion in Cirrhotic Patients With Hepatocellular Carcinoma: . Journal of Computer Assisted Tomography 2016;40:152-9. [DOI: 10.1097/rct.0000000000000331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
456 Liang P, Huang C, Liang SX, Li YF, Huang SX, Lian ZP, Liu JM, Tang Y, Lu HJ. Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity. Onco Targets Ther 2016;9:7169-75. [PMID: 27920555 DOI: 10.2147/OTT.S112290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
457 Li L, Wang H, Yang J, Jiang L, Yang J, Wu H, Wen T, Yan L. Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2018;8:12561. [PMID: 30135506 DOI: 10.1038/s41598-018-30906-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
458 Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, Minqing X, Jiaying Y. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore) 2014;93:e180. [PMID: 25474433 DOI: 10.1097/MD.0000000000000180] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
459 Wang F, Ye X, Zhai D, Dai W, Wu Y, Chen J, Chen W. Curcumin-loaded nanostructured lipid carrier induced apoptosis in human HepG2 cells through activation of the DR5/caspase-mediated extrinsic apoptosis pathway. Acta Pharm 2020;70:227-37. [PMID: 31955141 DOI: 10.2478/acph-2020-0003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
460 Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology 2015;205:764-73. [DOI: 10.2214/ajr.15.14825] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
461 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
462 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J. Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic. Journal of Gastroenterology and Hepatology 2018;34:1066-73. [DOI: 10.1111/jgh.14564] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
463 Kromrey M, Hori M, Goshima S, Kozaka K, Hyodo T, Nakamura Y, Nishie A, Tamada T, Shimizu T, Kanki A, Motosugi U. Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice. Eur Radiol 2020;30:281-90. [DOI: 10.1007/s00330-019-06358-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
464 Dhayat SA, Mardin WA, Köhler G, Bahde R, Vowinkel T, Wolters H, Senninger N, Haier J, Mees ST. The microRNA-200 family--a potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol 2014;110:430-8. [PMID: 24895326 DOI: 10.1002/jso.23668] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
465 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041-1053. [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
466 Eun HS, Lee BS, Kwon IS, Yun GY, Lee ES, Joo JS, Sung JK, Moon HS, Kang SH, Kim JS, Shin HJ, Kim TK, Chun K, Kim SH. Advantages of Laparoscopic Radiofrequency Ablation Over Percutaneous Radiofrequency Ablation in Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2586-2600. [PMID: 28744835 DOI: 10.1007/s10620-017-4688-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
467 Zhong C, Qiu S, Li J, Shen J, Zu Y, Shi J, Sui G. Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma. Phytomedicine 2019;59:152921. [PMID: 31055231 DOI: 10.1016/j.phymed.2019.152921] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
468 Lamba R, Fananazapir G, Corwin MT, Khatri VP. Diagnostic Imaging of Hepatic Lesions in Adults. Surgical Oncology Clinics of North America 2014;23:789-820. [DOI: 10.1016/j.soc.2014.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
469 Kim HS, Rotundo L, Yang JD, Kim D, Kothari N, Feurdean M, Ruhl C, Unalp-Arida A. Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States. J Viral Hepat. 2017;. [PMID: 28581638 DOI: 10.1111/jvh.12735] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
470 Nam JY, Lee JH, Bae J, Chang Y, Cho Y, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. Cancers (Basel) 2020;12:E2791. [PMID: 33003306 DOI: 10.3390/cancers12102791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
471 Tao LP, Fan XP, Fan YC, Zhao J, Gao S, Wang K. Combined detection of insulin-like growth factor-binding protein 7 promoter methylation improves the diagnostic efficacy of AFP in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2018;214:144-50. [PMID: 29108923 DOI: 10.1016/j.prp.2017.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
472 Hao QQ, Chen GY, Zhang JH, Sheng JH, Gao Y. Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96:e7496. [PMID: 28700498 DOI: 10.1097/md.0000000000007496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
473 Tang A, Cruite I, Sirlin CB. Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol. 2013;7:269-279. [PMID: 23445236 DOI: 10.1586/egh.13.3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
474 Lee JS, Kim MY, Park ER, Shen YN, Jeon JY, Cho EH, Park SH, Han CJ, Choi DW, Jang JJ, Suh KS, Hong J, Kim SB, Lee KH. TMEM165, a Golgi transmembrane protein, is a novel marker for hepatocellular carcinoma and its depletion impairs invasion activity. Oncol Rep 2018;40:1297-306. [PMID: 30015898 DOI: 10.3892/or.2018.6565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
475 Lee T, Wu J, Yu S, Lin J, Wu M, Wu C. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017;141:1307-14. [DOI: 10.1002/ijc.30784] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
476 Hung M, Lai W, Chen HH, Lee J, Lin Y, Hsiao J, Cheng Y, Shan Y, Su W, Wang J. Cost effectiveness of cancer treatment in Taiwan. Journal of the Formosan Medical Association 2016;115:609-18. [DOI: 10.1016/j.jfma.2016.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
477 Kennedy NA, Rodgers A, Altus R, McCormick R, Wundke R, Wigg AJ. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J 2013;43:772-7. [PMID: 23611607 DOI: 10.1111/imj.12166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
478 Reig M, Gazzola A, Di Donato R, Bruix J. Systemic treatment. Best Practice & Research Clinical Gastroenterology 2014;28:921-35. [DOI: 10.1016/j.bpg.2014.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
479 Kim MY, Kim YK, Park HJ, Park MJ, Lee WJ, Choi D. Diagnosis of focal liver lesions with gadoxetic acid-enhanced MRI: is a shortened delay time possible by adding diffusion-weighted imaging? J Magn Reson Imaging. 2014;39:31-41. [PMID: 24115329 DOI: 10.1002/jmri.24122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
480 Xu C, Huang Q, Zhang C, Xu W, Xu G, Zhao X, Liu X, Du Y. Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma. Ir J Med Sci 2018;187:621-8. [PMID: 29081064 DOI: 10.1007/s11845-017-1692-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
481 Sperling J, Justinger C, Schuld J, Ziemann C, Seidel R, Kollmar O. Intrahepatic cholangiocarcinoma in a transplant liver--selective internal radiation therapy followed by right hemihepatectomy: report of a case. World J Surg Oncol 2014;12:198. [PMID: 24980217 DOI: 10.1186/1477-7819-12-198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
482 Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HL, Sherman M, Hirschfield GM, Feld JJ. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. Journal of Hepatology 2018;68:92-9. [DOI: 10.1016/j.jhep.2017.07.033] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
483 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
484 Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, Chen R, Zhou H, Xiang X, Cai W, Wang H, Bao S, Xu Y, Gui H, Xie Q. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther 2018;18:1085-94. [PMID: 30182763 DOI: 10.1080/14712598.2018.1518423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
485 Sasaki K, Matsuda M, Ohkura Y, Kawamura Y, Inoue M, Hashimoto M, Ikeda K, Kumada H, Watanabe G. In hepatocellular carcinomas, any proportion of poorly differentiated components is associated with poor prognosis after hepatectomy. World J Surg 2014;38:1147-53. [PMID: 24305929 DOI: 10.1007/s00268-013-2374-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
486 Fan WZ, Zhang YQ, Yao W, Wang Y, Tan GS, Huang YH, Yang JY, Li JP. Is Emergency Transcatheter Hepatic Arterial Embolization Suitable for Spontaneously Ruptured Hepatocellular Carcinoma in Child-Pugh C Cirrhosis? J Vasc Interv Radiol 2018;29:404-412.e3. [PMID: 29249595 DOI: 10.1016/j.jvir.2017.09.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
487 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
488 Cheng JT, Tan NE, Volk ML. Utility of positron emission tomography-computed tomography scan in detecting residual hepatocellular carcinoma post treatment: Series of case reports. World J Gastrointest Oncol 2020;12:358-64. [PMID: 32206185 DOI: 10.4251/wjgo.v12.i3.358] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
489 Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. J Hepatol. 2015;62:690-700. [PMID: 25457198 DOI: 10.1016/j.jhep.2014.10.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 9.1] [Reference Citation Analysis]
490 Koduru P, Suzuki R, Lakhtakia S, Ramchandani M, Makmun D, Bhutani MS. Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma.J Hepatocell Carcinoma. 2015;2:143-149. [PMID: 27508203 DOI: 10.2147/JHC.S60868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
491 Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg. 2013;100:55-65. [PMID: 23212620 DOI: 10.1002/bjs.8995] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
492 Cao LP, Zhang C, Weng XY, Xie HY, Wu J, Zheng SS. Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells. Hepatobiliary Pancreat Dis Int 2020;19:295-8. [PMID: 32247719 DOI: 10.1016/j.hbpd.2020.03.003] [Reference Citation Analysis]
493 Bayle M, Clerc-Urmès I, Ayav A, Bronowicki JP, Petit I, Orry X, Laurent V. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. Abdom Radiol (NY) 2019;44:85-94. [PMID: 30054686 DOI: 10.1007/s00261-018-1714-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
494 Liu J, Liu Y, Huang J, Huang L, Zhao P. Real-time Monitoring of Contrast-enhanced Ultrasound for Radio Frequency Ablation. Open Med (Wars) 2017;12:474-80. [PMID: 29318194 DOI: 10.1515/med-2017-0066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
495 Cohen-hallaleh V, Guo L, Hosseini-nik H, Razaghi Kashani N, Menezes R, Jhaveri K. Does injection flow rate have an impact on arterial phase image degradation in liver MRI? A comparison of gadoxetic acid versus gadobutrol. Clinical Radiology 2017;72:994.e1-8. [DOI: 10.1016/j.crad.2017.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
496 Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. [PMID: 22913492 DOI: 10.1186/1745-6215-13-144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
497 Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, Lall C. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol. 2014;20:218-222. [PMID: 25032190 DOI: 10.3350/cmh.2014.20.2.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
498 Duffy MJ. Use of Biomarkers in Screening for Cancer. Adv Exp Med Biol 2015;867:27-39. [PMID: 26530358 DOI: 10.1007/978-94-017-7215-0_3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
499 Park YS, Lee CH, Kim JW, Shin S, Park CM. Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents? World J Gastroenterol. 2016;22:284-299. [PMID: 26755877 DOI: 10.3748/wjg.v22.i1.284] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
500 Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine. 2015;73:245-252. [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
501 Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol 2015;21:5654-62. [PMID: 25987792 DOI: 10.3748/wjg.v21.i18.5654] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
502 Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Tanaka K, Maeda S, Sakamoto N. Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. Hepatol Res. 2019;49:810-822. [PMID: 30920086 DOI: 10.1111/hepr.13338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
503 Tao J, Liu Z, Wang Y, Wang L, Yao B, Li Q, Wang C, Tu K, Liu Q. MiR-542-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting UBE3C. Biomed Pharmacother 2017;93:420-8. [PMID: 28666208 DOI: 10.1016/j.biopha.2017.06.070] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
504 Zhou P, Chen B, Miao X, Zhou J, Xiong L, Wen Y, Zou H. Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:823-31. [DOI: 10.1007/s11605-019-04123-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
505 Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, Pascal G, Laurent A, Levesque E, Maggi U, Feray C, Cherqui D, Castaing D, Azoulay D. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB (Oxford). 2015;17:611-623. [PMID: 25980326 DOI: 10.1111/hpb.12416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
506 Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018;18:138. [PMID: 30180810 DOI: 10.1186/s12876-018-0849-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
507 Aldámiz-Echevarría T, Berenguer J, Miralles P, Jiménez-Sousa MA, Carrero A, Pineda-Tenor D, Díez C, Tejerina F, Pérez-Latorre L, Bellón JM, Resino S. Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome. PLoS One 2016;11:e0148537. [PMID: 26849641 DOI: 10.1371/journal.pone.0148537] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
508 Qi LN, Ma L, Chen YY, Chen ZS, Zhong JH, Gong WF, Lu Y, Xiang BD, Li LQ. Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status. Ann Med 2020;52:21-31. [PMID: 31876201 DOI: 10.1080/07853890.2019.1709655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
509 Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, Zhu X, Xing BC. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. HPB (Oxford) 2019;21:425-33. [PMID: 30249510 DOI: 10.1016/j.hpb.2018.08.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
510 Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology 2018;48:103-14. [DOI: 10.1093/jjco/hyx180] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 19.5] [Reference Citation Analysis]
511 Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res 2019;11:1013-21. [PMID: 30774429 DOI: 10.2147/CMAR.S186678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
512 Chan AW, Chong CC, Mo FK, Wong J, Yeo W, Johnson PJ, Yu S, Lai PB, Chan AT, To KF, Chan SL. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1766-1772. [PMID: 26992142 DOI: 10.1111/jgh.13339] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
513 Dugum MF, Zein NN. Liver Transplantation for Hepatocellular Carcinoma. Clinical Liver Disease. 2016;7:36-39. [PMID: 31041025 DOI: 10.1002/cld.531] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
514 Lin WR, Hsu CW, Chen YC, Chang ML, Liang KH, Huang YH, Yeh CT. GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. Mol Clin Oncol 2014;2:630-40. [PMID: 24940508 DOI: 10.3892/mco.2014.294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
515 Ravi S, Singal AK. Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid. 2014;9:81-87. [PMID: 25114628 DOI: 10.2147/ce.s48626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
516 Li M, Wang Y, Jiang S, Gao Y, Zhang W, Hu S, Cheng X, Zhang C, Sun P, Ke W, Wang G, Song Z, Zhang Y, Zheng QC. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma. Nanomedicine (Lond) 2020;15:145-61. [PMID: 31782335 DOI: 10.2217/nnm-2018-0455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
517 Fujiwara N, Tateishi R, Kondo M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Masuzaki R, Nakagawa H. Cause-specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation. Eur J Gastroenterol Hepatol. 2014;26:1039-1046. [PMID: 25051219 DOI: 10.1097/meg.0000000000000161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
518 Fang ZT, Wang GZ, Zhang W, Qu XD, Liu R, Qian S, Zhu L, Zhou B, Wang JH. Transcatheter arterial embolization promotes liver tumor metastasis by increasing the population of circulating tumor cells. Onco Targets Ther 2013;6:1563-72. [PMID: 24235842 DOI: 10.2147/OTT.S52973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
519 Huang JY, Li JW, Lu Q, Luo Y, Lin L, Shi YJ, Li T, Liu JB, Lyshchik A. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma. Radiology. 2020;294:329-339. [PMID: 31793849 DOI: 10.1148/radiol.2019191086] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
520 Guo J, Jing R, Zhong JH, Dong X, Li YX, Liu YK, Huang TR, Zhang CY. Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics. Oncotarget 2017;8:62011-28. [PMID: 28977922 DOI: 10.18632/oncotarget.18782] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
521 Kitzing YX, Ng BH, Kitzing B, Waugh R, Kench JG, Strasser SI, Mccormack S. Washout of hepatocellular carcinoma on portal venous phase of multidetector computed tomography in a pre-transplant population: Portal venous phase washout of HCCs. Journal of Medical Imaging and Radiation Oncology 2015;59:673-80. [DOI: 10.1111/1754-9485.12347] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
522 Kim SS, Kang TW, Song KD, Cho SK, Lee MW, Rhim H, Sinn DH, Jung SH. Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. Clin Radiol 2017;72:141-9. [PMID: 27742104 DOI: 10.1016/j.crad.2016.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
523 Cox MC, Aloe-Spiriti MA, Cavalieri E, Alma E, Gigante E, Begini P, Rebecchini C, Delle Fave G, Marignani M. HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions. World J Gastrointest Oncol 2012;4:46-53. [PMID: 22468183 DOI: 10.4251/wjgo.v4.i3.46] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
524 Aboulafia DM. Cancer screening in women living with HIV infection. Womens Health (Lond) 2017;13:68-79. [PMID: 28952428 DOI: 10.1177/1745505717731970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
525 Girotra M, Soota K, Dhaliwal AS, Abraham RR, Garcia-Saenz-de-Sicilia M, Tharian B. Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? World J Gastrointest Endosc. 2018;10:56-68. [PMID: 29467916 DOI: 10.4253/wjge.v10.i2.56] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
526 Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:199-210. [PMID: 24077865 DOI: 10.1007/s00432-013-1528-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
527 Tsai MC, Lin CC, Chen DW, Liu YW, Wu YJ, Yen YH, Huang PY, Yao CC, Chuang CH, Hsiao CC. The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. Medicina (Kaunas) 2021;57:574. [PMID: 34199695 DOI: 10.3390/medicina57060574] [Reference Citation Analysis]
528 Yadav DK, Hua YF, Bai X, Lou J, Que R, Gao S, Zhang Y, Wang J, Xie Q, Edoo MIA, Chutturghoon VK, Liang T. ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2019;2019:8589402. [PMID: 31285743 DOI: 10.1155/2019/8589402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
529 Eritja N, Chen BJ, Rodríguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, Encinas M, Ribera J, Reventós J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navàs D. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017;13:608-24. [PMID: 28055301 DOI: 10.1080/15548627.2016.1271512] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
530 Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J;  iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64:1178-1188. [PMID: 27481548 DOI: 10.1002/hep.28744] [Cited by in Crossref: 132] [Cited by in F6Publishing: 98] [Article Influence: 26.4] [Reference Citation Analysis]
531 Ou Y, Huang J, Yang L. The prognostic significance of pretreatment serum γ-glutamyltranspeptidase in primary liver cancer: a meta-analysis and systematic review. Biosci Rep 2018;38:BSR20181058. [PMID: 30389711 DOI: 10.1042/BSR20181058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
532 Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945-952. [PMID: 29055908 DOI: 10.1136/gutjnl-2017-314904] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 19.3] [Reference Citation Analysis]
533 Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu’ L, Rapaccini G. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int. 2015;35:223-231. [PMID: 25074434 DOI: 10.1111/liv.12649] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
534 Yu MH, Lee JM, Yoon JH, Baek JH, Han JK, Choi BI, Flohr TG. Low tube voltage intermediate tube current liver MDCT: sinogram-affirmed iterative reconstruction algorithm for detection of hypervascular hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201:23-32. [PMID: 23789655 DOI: 10.2214/ajr.12.10000] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 5.9] [Reference Citation Analysis]
535 Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci. 2014;11:707-712. [PMID: 24843320 DOI: 10.7150/ijms.8764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
536 Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 2014;9:e98612. [PMID: 24874413 DOI: 10.1371/journal.pone.0098612] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
537 Fathy AH, Bashandy MA, Bashandy SA, Mansour AM, Elsadek B. Sequential analysis and staging of a diethylnitrosamine-induced hepatocellular carcinoma in male Wistar albino rat model. Can J Physiol Pharmacol 2017;95:1462-72. [DOI: 10.1139/cjpp-2017-0413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
538 Min JH, Kim YK, Sinn DH, Choi SY, Jeong WK, Lee WJ, Ha SY, Ahn S, Kim MJ. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdom Radiol (NY) 2018;43:2309-20. [PMID: 29470629 DOI: 10.1007/s00261-018-1480-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
539 Meloni MF, Chiang J, Laeseke PF, Dietrich CF, Sannino A, Solbiati M, Nocerino E, Brace CL, Lee FT Jr. Microwave ablation in primary and secondary liver tumours: technical and clinical approaches. Int J Hyperthermia 2017;33:15-24. [PMID: 27416729 DOI: 10.1080/02656736.2016.1209694] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 10.2] [Reference Citation Analysis]
540 Siramolpiwat S, Punjachaipornpon T, Pornthisarn B, Vilaichone RK, Chonprasertsuk S, Tangaroonsanti A, Bhanthumkomol P, Phumyen A, Yasiri A, Kaewmanee M. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization. Dig Dis Sci 2019;64:3337-45. [PMID: 31073737 DOI: 10.1007/s10620-019-05652-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
541 Chuncharunee A, Siramolpiwat S. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment. Asian Pac J Cancer Prev 2017;18:1697-701. [PMID: 28670891 DOI: 10.22034/APJCP.2017.18.6.1697] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
542 Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825-1833. [PMID: 24499831 DOI: 10.1245/s10434-014-3510-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
543 Matsukuma S, Sakamoto K, Tokuhisa Y, Tokumitsu Y, Matsui H, Kanekiyo S, Tomochika S, Iida M, Suzuki N, Takeda S, Ueno T, Wada H, Kobayashi S, Saeki I, Eguchi H, Sakon M, Sakaida I, Nagano H. Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer-B hepatocellular carcinoma. Oncol Lett 2018;16:6383-92. [PMID: 30344760 DOI: 10.3892/ol.2018.9420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
544 Ye J, Huang G, Zhang X, Xu M, Zhou X, Lin M, Xie X, Xie X. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. International Journal of Hyperthermia 2019;36:55-64. [DOI: 10.1080/02656736.2018.1530460] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
545 Kaibori M, Kon M, Kitawaki T, Kawaura T, Hasegawa K, Kokudo N, Ariizumi S, Beppu T, Ishizu H, Kubo S, Kamiyama T, Takamura H, Kobayashi T, Kim DS, Wang HJ, Kim JM, Han DH, Park SJ, Kang KJ, Hwang S, Roh Y, You YK, Joh JW, Yamamoto M. Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2017;24:616-26. [PMID: 28887834 DOI: 10.1002/jhbp.502] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
546 Peeraphatdit T, Naksuk N, Phatharacharukul P, Bell BJ, Ricci P. Adherence to diagnostic guidelines of hepatocellular carcinoma: 12-year experience in a veterans affairs medical center. Eur J Gastroenterol Hepatol 2015;27:846-52. [PMID: 25961665 DOI: 10.1097/MEG.0000000000000349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
547 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
548 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
549 Hsu CY, Liu PH, Hsia CY, Lee YH, Nagaria TS, Lee RC, Lin HC, Huo TI. Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. Ann Surg Oncol. 2016;23:994-1002. [PMID: 26487000 DOI: 10.1245/s10434-015-4929-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
550 Choi W, Yu SJ, Ahn H, Cho H, Cho YY, Lee M, Yoo J, Cho Y, Lee DH, Cho EJ, Lee J, Kim YJ, Yoon J. A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma? Digestive and Liver Disease 2017;49:1273-9. [DOI: 10.1016/j.dld.2017.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol 2019;2019:6298502. [PMID: 31636667 DOI: 10.1155/2019/6298502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
552 Makino Y, Imai Y, Ohama H, Igura T, Kogita S, Sawai Y, Fukuda K, Takamura M, Ohashi H, Murakami T. Ultrasonography Fusion Imaging System Increases the Chance of Radiofrequency Ablation for Hepatocellular Carcinoma with Poor Conspicuity on Conventional Ultrasonography. Oncology 2013;84:44-50. [DOI: 10.1159/000345889] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
553 Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol 2016;2016:4385643. [PMID: 27471521 DOI: 10.1155/2016/4385643] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
554 Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol 2019;17:45. [PMID: 30823932 DOI: 10.1186/s12957-019-1577-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
555 Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol. 2013;5:521-527. [PMID: 24179611 DOI: 10.4254/wjh.v5.i10.521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
556 Ardelt MA, Pachmayr J. The long non-coding RNA H19 - a new player in hepatocellular carcinoma. Cell Stress 2017;1:4-6. [PMID: 31223144 DOI: 10.15698/cst2017.10.102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
557 Vogel A, Gupta S, Zeile M, von Haken R, Brüning R, Lotz G, Vahrmeijer A, Vogl T, Wacker F. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. Adv Ther 2017;33:2122-38. [PMID: 27798773 DOI: 10.1007/s12325-016-0424-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
558 Xu L, Wu J, Lu W, Yang C, Liu H. Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Transplant Proc. 2019;51:3338-3346. [PMID: 31732203 DOI: 10.1016/j.transproceed.2019.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
559 Min JH, Kim YK, Choi S, Jeong WK, Lee WJ, Ha SY, Ahn S, Ahn HS. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum. European Journal of Radiology 2017;92:1-10. [DOI: 10.1016/j.ejrad.2017.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
560 Li W, Dong X, He C, Tan G, Li Z, Zhai B, Feng J, Jiang X, Liu C, Jiang H, Sun X. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2019;38:183. [PMID: 31053148 DOI: 10.1186/s13046-019-1177-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 25.0] [Reference Citation Analysis]
561 Kim JH, Sinn DH, Gwak G, Kang W, Paik Y, Choi MS, Lee JH, Koh KC, Paik SW. Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients: Insulin resistance and hepatitis B. Journal of Gastroenterology and Hepatology 2017;32:1100-6. [DOI: 10.1111/jgh.13647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
562 Poliektov N, Johnson DT. Treatment of Liver Tumors with Transarterial Chemoembolization. Semin Intervent Radiol 2018;35:350-5. [PMID: 30402018 DOI: 10.1055/s-0038-1673423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
563 Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, Kim TY, Sohn JH, Tak WY, Han KH. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809-20. [PMID: 25627342 DOI: 10.1002/hep.27723] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]
564 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
565 Santambrogio R, Barabino M, Scifo G, Costa M, Giovenzana M, Opocher E. Effect of Age (over 75 Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. J Gastrointest Surg 2017;21:657-65. [DOI: 10.1007/s11605-016-3354-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
566 Lei J, Zhong J, Luo Y, Yan L, Zhu J, Wang W, Li B, Wen T, Yang J; Liver Surgery Group. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget 2017;8:91328-42. [PMID: 29207647 DOI: 10.18632/oncotarget.20511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
567 Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transpl 2016;22:1491-500. [DOI: 10.1002/lt.24615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
568 Qian LJ, Zhu J, Zhuang ZG, Xia Q, Liu Q, Xu JR. Spectrum of multilocular cystic hepatic lesions: CT and MR imaging findings with pathologic correlation. Radiographics. 2013;33:1419-1433. [PMID: 24025933 DOI: 10.1148/rg.335125063] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 6.7] [Reference Citation Analysis]
569 Kabir T, Syn NL, Guo Y, Lim KI, Goh BKP. Laparoscopic liver resection for huge (≥10 cm) hepatocellular carcinoma: A coarsened exact-matched single-surgeon study. Surg Oncol 2021;37:101569. [PMID: 33839442 DOI: 10.1016/j.suronc.2021.101569] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka AO. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Invest New Drugs 2014;32:762-8. [PMID: 24737402 DOI: 10.1007/s10637-014-0097-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
571 Li P, Huang W, Wang F, Ke YF, Gao L, Shi KQ, Zhou MT, Chen BC. Nomograms based on inflammatory biomarkers for predicting tumor grade and micro-vascular invasion in stage I/II hepatocellular carcinoma. Biosci Rep. 2018;38. [PMID: 30254101 DOI: 10.1042/bsr20180464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
572 Nomair AM, Issa NM, Madkour MA, Shamseya MM. The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma. Clin Exp Hepatol 2020;6:20-7. [PMID: 32166120 DOI: 10.5114/ceh.2020.93052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
573 Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 2015;63:722-732. [PMID: 26026875 DOI: 10.1016/j.jhep.2015.05.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
574 Cho YS, Kim JW, Seon HJ, Cho JY, Park JH, Kim HJ, Choi YD, Hur YH. Intrahepatic adrenocortical adenoma arising from adrenohepatic fusion mimicking hepatic malignancy: Two case reports. Medicine (Baltimore) 2019;98:e15901. [PMID: 31169702 DOI: 10.1097/MD.0000000000015901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
575 Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736-744. [PMID: 24883123 DOI: 10.7150/thno.8725] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
576 Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) 2015;17:52-65. [PMID: 24961288 DOI: 10.1111/hpb.12273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
577 Lee DW, Lee KH, Kim HJ, Kim TY, Kim JS, Han SW, Oh DY, Kim JH, Im SA, Kim TY. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. BMC Cancer 2018;18:252. [PMID: 29506478 DOI: 10.1186/s12885-018-4039-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
578 Gao XH, Zhang SS, Chen H, Wang YH, Yuan CH, Wang FB. Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection. Front Physiol 2017;8:480. [PMID: 28769812 DOI: 10.3389/fphys.2017.00480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
579 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0161303. [PMID: 27537374 DOI: 10.1371/journal.pone.0161303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
580 Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv Anat Pathol. 2011;18:438-445. [PMID: 21993269 DOI: 10.1097/pap.0b013e318234abb4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
581 Ertel AE, Shah SA. Surgical Approaches to Hepatocellular Carcinoma. Semin Roentgenol 2016;51:88-94. [PMID: 27105963 DOI: 10.1053/j.ro.2016.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
582 Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up. Acta Radiol 2018;59:765-72. [DOI: 10.1177/0284185117732805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
583 Hoang JK, Yang HI, Le A, Nguyen NH, Lin D, Vu VD, Chaung K, Nguyen V, Trinh HN, Li J, Zhang JQ, Chen CJ, Nguyen MH. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) 2016;95:e4433. [PMID: 27495067 DOI: 10.1097/MD.0000000000004433] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
584 Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, Hershman DL, Brown RS Jr, Neugut AI, Emond J, Kato T, Samstein B, Faleck D, Karagozian R. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology 2015;88:57-68. [PMID: 25300295 DOI: 10.1159/000367971] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
585 Xiang X, Lau W, Wu Z, Zhao C, Ma Y, Xiang B, Zhu J, Zhong J, Li L. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus:a multicenter study. European Journal of Surgical Oncology 2019;45:1460-7. [DOI: 10.1016/j.ejso.2019.03.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
586 Granito A, Galassi M, Piscaglia F, Romanini L, Lucidi V, Renzulli M, Borghi A, Grazioli L, Golfieri R, Bolondi L. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther. 2013;37:355-363. [PMID: 23199022 DOI: 10.1111/apt.12166] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
587 Muir AJ. Surgical clearance for the patient with chronic liver disease. Clin Liver Dis. 2012;16:421-433. [PMID: 22541707 DOI: 10.1016/j.cld.2012.03.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
588 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 79] [Article Influence: 31.0] [Reference Citation Analysis]
589 Zhou C, Sun J, Zheng Z, Weng J, Atyah M, Zhou Q, Chen W, Zhang Y, Huang J, Yin Y, Mao H, Zhang Z, Yi Y, Ren N. High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. Ann Transl Med 2020;8:466. [PMID: 32395510 DOI: 10.21037/atm.2020.03.92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
590 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
591 Smolock AR, Cristescu MM, Hinshaw A, Woo KM, Wells SA, Ziemlewicz TJ, Lubner MG, Dalvie PS, Louis Hinshaw J, Brace CL. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY). 2018;43:2497-2504. [PMID: 29450606 DOI: 10.1007/s00261-018-1464-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
592 Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol. 2017;9:1322-1331. [PMID: 29359015 DOI: 10.4254/wjh.v9.i36.1322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
593 Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, Kim BK, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol Biol Phys 2017;99:396-406. [PMID: 28871990 DOI: 10.1016/j.ijrobp.2017.05.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
594 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
595 Chen QW, Teng WJ, Chen Q. Chest wall hernia induced by high intensity focused ultrasound treatment of unresectable massive hepatocellular carcinoma: A case report. Oncol Lett 2016;12:627-30. [PMID: 27347191 DOI: 10.3892/ol.2016.4618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
596 Nishigaki Y, Hayashi H, Tomita E, Suzuki Y, Watanabe N, Watanabe S, Watanabe C, Takagi Y, Kato T, Naiki T. Usefulness of contrast-enhanced ultrasonography using Sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma: CEUS assessment of therapeutic effect of PRFA. Hepatol Res 2015;45:432-40. [DOI: 10.1111/hepr.12370] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
597 Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017;9:469-76. [PMID: 28396717 DOI: 10.4254/wjh.v9.i9.469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
598 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
599 D'inca H, Piot O, Diebold MD, Piardi T, Marcus C, Burde F, Sommacale D, Manfait M, Thiéfin G. Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. J Vasc Interv Radiol 2017;28:804-10. [PMID: 28532743 DOI: 10.1016/j.jvir.2017.01.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
600 Bieze M, Klümpen H, Verheij J, Beuers U, Phoa SS, van Gulik TM, Bennink RJ. Diagnostic accuracy of 18 F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma. Hepatology 2014;59:996-1006. [DOI: 10.1002/hep.26781] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
601 El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627-35. [DOI: 10.1111/liv.12637] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
602 Lee JM, Zech CJ, Bolondi L, Jonas E, Kim MJ, Matsui O, Merkle EM, Sakamoto M, Choi BI. Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol. 2011;12:403-415. [PMID: 21852900 DOI: 10.3348/kjr.2011.12.4.403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
603 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Eur J Gastroenterol Hepatol 2019;31:1452-9. [PMID: 31082998 DOI: 10.1097/MEG.0000000000001434] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
604 Cheng RG, Bhattacharya R, Yeh MM, Padia SA. Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis. Journal of Vascular and Interventional Radiology 2015;26:1184-8. [DOI: 10.1016/j.jvir.2015.05.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
605 Castilla-lièvre M, Franco D, Gervais P, Kuhnast B, Agostini H, Marthey L, Désarnaud S, Helal B. Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016;43:852-9. [DOI: 10.1007/s00259-015-3241-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
606 Yang JF, Lo CH, Lee MS, Lin CS, Dai YH, Shen PC, Chao HL, Huang WY. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol 2019;14:180. [PMID: 31640728 DOI: 10.1186/s13014-019-1382-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
607 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget 2016;7:6639-48. [PMID: 26735891 DOI: 10.18632/oncotarget.6781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
608 Dietrich CF, Potthoff A, Helmberger T, Ignee A, Willmann JK; on behalf of the CEUS LI-RADS Working Group. Standardisierte Befundung und Dokumentation der Kontrastmittelsonografie der Leber (CEUS LI-RADS). Z Gastroenterol 2018;56:499-506. [DOI: 10.1055/s-0043-124874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
609 Facciorusso A, Abd El Aziz MA, Cincione I, Cea UV, Germini A, Granieri S, Cotsoglou C, Sacco R. Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study. Biomedicines 2020;8:E399. [PMID: 33050084 DOI: 10.3390/biomedicines8100399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
610 Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH. High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. Transl Oncol 2013;6:311-8. [PMID: 23730411 DOI: 10.1593/tlo.12418] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 8.6] [Reference Citation Analysis]
611 Lee SJ, Cho EH, Kim R, Kim YH, Lim CS, Kim SB. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg 2015;19:98-102. [PMID: 26379730 DOI: 10.14701/kjhbps.2015.19.3.98] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
612 Chang W, Lu S, Rau K, Huang C, Lee K. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences 2018;34:391-9. [DOI: 10.1016/j.kjms.2018.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
613 Klompenhouwer EG, Dresen RC, Verslype C, Laenen A, De Hertogh G, Deroose CM, Bonne L, Vandevaveye V, Maleux G. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation. Cardiovasc Intervent Radiol 2017;40:1882-90. [DOI: 10.1007/s00270-017-1739-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
614 Kudo M. Diagnostic imaging of hepatocellular carcinoma: Recent progress. Oncology. 2011;81 Suppl 1:73-85. [PMID: 22212940 DOI: 10.1159/000333265] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
615 Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 2014;105:354-8. [PMID: 24438504 DOI: 10.1111/cas.12353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
616 Shi Z, Liu J, Yu X, Huang J, Shen S, Zhang Y, Han R, Ge N, Yang Y. Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients. Ann Surg Oncol 2016;23:211-7. [PMID: 25824262 DOI: 10.1245/s10434-015-4515-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
617 Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821-829. [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014] [Cited by in Crossref: 473] [Cited by in F6Publishing: 456] [Article Influence: 52.6] [Reference Citation Analysis]
618 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
619 Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers (Basel) 2020;12:E2906. [PMID: 33050527 DOI: 10.3390/cancers12102906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
620 Ronot M, Vilgrain V. Hepatocellular carcinoma: diagnostic criteria by imaging techniques. Best Pract Res Clin Gastroenterol. 2014;28:795-812. [PMID: 25260309 DOI: 10.1016/j.bpg.2014.08.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
621 Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography. Liver Int. 2017;37:592-599. [PMID: 27804192 DOI: 10.1111/liv.13297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
622 Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. Liver Int 2018;38:2028-39. [PMID: 29745475 DOI: 10.1111/liv.13877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
623 Vasuri F, Malvi D, Bonora S, Fittipaldi S, Renzulli M, Tovoli F, Golfieri R, Bolondi L, D'errico A. From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. Histopathology 2018;72:414-22. [DOI: 10.1111/his.13389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
624 Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: The current status. The Surgeon 2020;18:178-86. [DOI: 10.1016/j.surge.2019.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
625 N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O. Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. Liver Cancer 2019;8:172-85. [PMID: 31192154 DOI: 10.1159/000489319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
626 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
627 Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, Forest-Tramoy D, Josse T, Reinicke D, Garcia M, Luc A, Baumann C, Ayav A, Laurent V, Hollenbach M, Ripoll C, Guéant-Rodriguez RM, Namour F, Zipprich A, Fleischhacker M, Bronowicki JP, Guéant JL. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine 2018;30:138-47. [PMID: 29627389 DOI: 10.1016/j.ebiom.2018.03.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 17.0] [Reference Citation Analysis]
628 Rao PN. Nodule in Liver: Investigations, Differential Diagnosis and Follow-up. J Clin Exp Hepatol 2014;4:S57-62. [PMID: 25755612 DOI: 10.1016/j.jceh.2014.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
629 Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy. Liver Int 2019;39:1964-74. [DOI: 10.1111/liv.14197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
630 Pectasides E, Miksad R, Pyatibrat S, Srivastava A, Bullock A. Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature. Dig Dis Sci 2016;61:2749-54. [PMID: 27038447 DOI: 10.1007/s10620-016-4141-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
631 Torzilli G, Donadon M, Belghiti J, Kokudo N, Takayama T, Ferrero A, Nuzzo G, Vauthey J, Choti MA, De Santibanes E, Makuuchi M. Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the “HCC East & West Study Group”. J Gastrointest Surg 2016;20:1154-62. [DOI: 10.1007/s11605-016-3132-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
632 Kim R, Jeong WK, Kang TW, Song KD, Lee MW, Ahn SH, Rhim H. Intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma: relationship with portal hypertension. Acta Radiol 2019;60:1609-18. [DOI: 10.1177/0284185119842830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
633 Chou CT, Chou JM, Chang TA, Huang SF, Chen CB, Chen YL, Chen RC. Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. World J Gastroenterol. 2013;19:7433-7439. [PMID: 24259975 DOI: 10.3748/wjg.v19.i42.7433] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
634 Song KD, Kim SH, Lim HK, Jung SH, Sohn I, Kim HS. Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging. Eur Radiol. 2015;25:2789-2796. [PMID: 25735515 DOI: 10.1007/s00330-015-3680-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
635 Chen L, Ren Y, Sun T, Cao Y, Yan L, Zhang W, Ouyang T, Zheng C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. Cancer Med 2021;10:3715-25. [PMID: 33960697 DOI: 10.1002/cam4.3923] [Reference Citation Analysis]
636 Cha DI, Lee MW, Rhim H, Choi D, Kim YS, Lim HK. Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations. Korean J Radiol 2013;14:240-7. [PMID: 23483664 DOI: 10.3348/kjr.2013.14.2.240] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
637 Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-1244. [PMID: 26502405 DOI: 10.1038/ni.3290] [Cited by in Crossref: 141] [Cited by in F6Publishing: 130] [Article Influence: 23.5] [Reference Citation Analysis]
638 Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol. 2014;20:17483-17490. [PMID: 25516662 DOI: 10.3748/wjg.v20.i46.17483] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
639 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
640 Seleem M, Hassany M. Narrow Band Imaging: A Novel Technique for Immediate Evaluation of Efficacy in Laparoscopic Radiofrequency Ablation of Exophytic Hepatocellular Carcinoma. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2018;28:282-6. [DOI: 10.1097/sle.0000000000000547] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
641 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
642 Li R, Li D, Jia G, Li X, Sun G, Zuo C. Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer. Front Oncol 2020;10:551622. [PMID: 33569342 DOI: 10.3389/fonc.2020.551622] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
643 Kim HY, Kim CW, Choi JY, Park CH, Lee CD, Yim HW. A Decade-old Change in the Screening Rate for Hepatocellular Carcinoma Among a Hepatitis B Virus-infected Population in Korea. Chin Med J (Engl) 2016;129:15-21. [PMID: 26712427 DOI: 10.4103/0366-6999.172551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
644 Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol 2020;26:364-75. [PMID: 32466635 DOI: 10.3350/cmh.2020.0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
645 Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, Ramirez Morales R, Biasiolo A, Zanus G, Zali N. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer. 2014;110:2708-2715. [PMID: 24809782 DOI: 10.1038/bjc.2014.246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
646 Kim HD, An J, Kim JH, Gwon DI, Shin JH, Ko GY, Yoon HK, Sung KB, Kim KM, Lee HC. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol 2016;27:504-13. [PMID: 26896049 DOI: 10.1016/j.jvir.2015.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
647 Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med. 2016;32:116-120. [PMID: 27413729 DOI: 10.1159/000445730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
648 Donahue LA, Kulik L, Baker T, Ganger DR, Gupta R, Memon K, Abecassis MM, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013;24:74-80. [PMID: 23273699 DOI: 10.1016/j.jvir.2012.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
649 Jha RC, Zanello PA, Nguyen XM, Pehlivanova M, Johnson LB, Fishbein T, Shetty K. Small hepatocellular carcinoma: MRI findings for predicting tumor growth rates. Acad Radiol. 2014;21:1455-1464. [PMID: 25300723 DOI: 10.1016/j.acra.2014.06.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
650 Vilarinho S, Taddei TH. New frontier in liver cancer treatment: oncolytic viral therapy. Hepatology 2014;59:343-6. [PMID: 23836532 DOI: 10.1002/hep.26605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
651 Marti J, Giacca M, Alshebeeb K, Bahl S, Hua C, Horn JC, Bouayache J, Patel R, Facciuto M, Schwartz M, Florman S, Kim E, Gunasekaran G. Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience. Journal of Vascular and Interventional Radiology 2018;29:920-6. [DOI: 10.1016/j.jvir.2018.01.780] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
652 Huang XW, Huang Y, Chen LD, Wang Z, Yang Z, Liu JY, Xie XY, Lu MD, Shen SL, Wang W. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma. J Med Ultrason (2001). 2018;45:231-241. [PMID: 29052791 DOI: 10.1007/s10396-017-0834-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
653 Kim JW, Lee CH, Kim SB, Park BN, Park YS, Lee J, Park CM. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules. J Magn Reson Imaging. 2017;45:1599-1608. [PMID: 27726242 DOI: 10.1002/jmri.25493] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
654 Chen P, Kao W, Chiou Y, Hung H, Su C, Chou Y, Huo T, Huang Y, Wu W, Chao Y, Lin H, Wu J. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology 2013;12:263-73. [DOI: 10.1016/s1665-2681(19)31365-1] [Cited by in Crossref: 15] [Article Influence: 1.9] [Reference Citation Analysis]
655